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Summary 
Forensic toxicology is concerned with the analysis of biological specimens to 
detect the presence of drugs or poisons that have been previously administered. 
Traditional samples used for this purpose have been blood, urine and body organs, but 
also in the last decade, other (alternative) samples have become widely used. One 
notable example is hair, which provides a wide detection window for prior drug use. 
This thesis examines the use of nail as an alternative biological specimen in 
forensic toxicology. Nail is a difficult analytical matrix from which to extract drugs 
because of its tough physical composition, based on keratin. Previously the keratin had 
been compulsorily dissolved with an alkaline solution. However, alkaline hydrolysis of 
the fingernail often chemically changed the target analytes, for example esters were 
hydrolysed to alcohols and carboxylic acids. 
The initial part of the project investigated the use of a cryogenic grinding method 
for fingernail clippings. Grinding at liquid nitrogen temperatures was found to be an 
effective procedure and the conditions were optimised to a two or three cycle programme 
of freezing and grinding. 
Small particle sizes were obtained of approximate size 1 µm. It was established 
that drugs could be extracted directly from nail powder with a range of solvents without 
the need for alkaline hydrolysis. Methanol was found to be the most effective extraction 
solvent, which also gave the lowest number of co-extracted interfering compounds. 
This procedure was subsequently used with nail samples from different types of 
forensic cases, including cannabis, heroin and steroid abusers. 
Cryogenic grinding of nail was evaluated as an extraction method for cannabinoids 
in nail clippings from chronic cannabis smokers. This method was also compared to the 
alkaline hydrolysis method. Fingernail clippings were collected with prior informed 
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consent from volunteers attending the Edinburgh Drug Addiction Study (EDAS) clinic. 
The collected nail clippings were decontaminated and divided into two groups: the first 
group was extracted with methanol after pulverisation in a liquid nitrogen cryogenic mill; 
the second was extracted with ethyl acetate after hydrolysis in sodium hydroxide. In both 
groups deuterated cannabinoids were used as internal standards. Both sets of extracts 
were derivatised with BSTFA before being analysed by gas chromatography - mass 
spectrometry (GC-MS). 
Cannabidiol, A9-tetrahydrocannabinol and 11-hydroxy-A'-tetrahydrocannabi- 
nol were quantified in both sets of extracts. 11-nor-A'-tetrahydrocannabinol-9- 
carboxylic acid was only identified and quantified in the extracts resulting from the 
cryogenic grinding method. 
Cannabinoid concentrations were very low, in the range 0-4 ng/mg. These results 
strongly support the use of nail as a biological specimen for the detection and 
quantification of past exposure to cannabis, and secondly, they indicate that grinding with 
a cryogenic mill is a useful procedure, which yields simultaneous results for the primary 
psychoactive cannabinoid and its metabolites. 
Cryogenic grinding was then evaluated for the extraction of opioids in nail in 
comparison with the conventional alkaline hydrolysis method. Finger and toe nails were 
collected from donors with informed consent. 
As before, these nails were decontaminated and divided into two groups. The first 
group was extracted with methanol after cryogenic grinding and the second was extracted 
by solid phase extraction after hydrolysis in sodium hydroxide solution. 
Deuterated methadone and opioids were used as internal standards and the extracts 
were analysed by GC-MS as trimethylsilyl derivatives. Morphine, codeine, methadone, 
papaverine and noscapine were detected and quantified in both sets of extracts. In 
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addition, heroin, 6-monoacetylmorphine and 6-acetylcodeine could be quantified in 
methanolic extracts from the cryogenic extraction method but not from the alkaline 
hydrolysis method. 
Concentrations were also very low, in the range 0-25 ng/mg of nail. This is the first 
time heroin was detected in nail, along with codeine, 6-acetylcodeine, papaverine and 
noscapine. The presence of these components suggests that the specimen donors took 
street heroin. Papaverine and noscapine, alkaloids in opium, have not previously been 
detected in urine or blood. 
Cryogenic grinding was subsequently used for extraction of endogenous and 
anabolic steroids from nail clippings of doping abusers to show that both can be detected, 
as in hair. This method was compared to blood (plasma) and urine samples analysed at 
the same time. 
Fingernail clippings from users of anabolic steroids (including testosterone esters, 
stanozolol and methenolone acetate) were obtained from the Institute of Doping 
Analysis/Sports Biochemistry, Kreischa. Blank nail and urine samples were obtained 
from volunteers. 
The nail samples were decontaminated, pulverised and extracted with methanol/ 
ethyl acetate (7: 3, v/v). Deuterated anabolic steroids (5a-estran-3ß-of-17-one-d3, 
testosterone-d3, and stanozolol-d3) and medroxyprogesterone were used as internal 
standards. 
The extracts were converted to TMS derivatives with MSTFA/NH4I/2- 
mercaptoethanol and analysed by GC-MS in the EI + full scan and SIM modes. 
Endogenous steroids were identified and quantified in the nail samples from both steroid 
users and non-users. 
Concentrations in nail were low, in the pg/mg range: (androsterone (1.5-12.8 
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pg/mg), etiocholanolone, dehydroepiandrosterone (1.4-25.3 pg/mg), epiandrosterone 
(0.7-14.3 pg/mg), epitestosterone (0.6-11.0 pg/mg) and testosterone (0.6-25.0 pg/mg). 
Also, elevated concentrations of testosterone in nail were positively associated with 
high concentrations in plasma and urine. However, although the analytical results 
provided evidence for the presence of anabolic steroids in the samples from steroid users, 
including testosterone and its isocaproate and enanthate esters, at low concentrations, it 
has not yet been possible to confirm this due to interference from other endogenous 
substances. 
Nail remains a potential, but still to be confirmed, alternative biological specimen 
to hair for the detection of past exposure to doping steroids. 
With permission of the Faculty of Science, part of the work for this thesis was 
carried out at an external institution, the Identification Research Laboratory, National 
Research Institute of Police Science, Tokyo. 
Pyrolysis GC-MS (Py-GC-MS) and MALDI-TOF mass spectrometry (MALDI- 
TOF-MS) were evaluated for the direct identification of illicit drugs within the nail 
matrix and in very small fingernail samples. Opium alkaloids and opioids were used as 
test compounds. 
The results showed that opium alkaloids could be detected amidst a large amount of 
impurity resulting from the thermal degradation of samples by Py-GC-MS analysis. 
Moreover, target analytes could be detected easily in the MALDI-TOF-MS analysis 
by a simple analytical procedure. 
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1. Introduction 
Forensic toxicology is the study of poisons and of cases of poisoning for the 
purposes of a medico-legal enquiry [1,2]. In different jurisdictions, the scope of the 
subject varies and can include fatalities, non-fatal poisoning, drugs in sport, road traffic 
safety, drug abuse monitoring in different contexts such as drug clinics, prison inmates 
and employment screening. 
In the field of forensic toxicology, it is extremely important to determine promptly 
and accurately whether a person has used an illicit drug. Blood, urine, and internal organs 
have traditionally been used as samples to detect the presence of illicit drugs. As many 
new analytical methods were developed with scientific advancement through the ages, 
we have reached the stage when even amounts of an illicit drug can be analysed by high 
sensitivity in a small amount of blood and urine. 
Blood, urine, and internal organs are considered to be the first generation of 
samples in the study of forensic toxicology. The second generation of samples appeared 
in the 1980's when hair, saliva, and sweat, amongst others began to be used as alternatives 
to blood. 
Drugs taken into the human body are promptly metabolised and excreted out of the 
body. Therefore, an examination of the components of drugs in blood and urine should 
collect the samples at an early stage after administration. The feature of the first 
generation samples is that obtaining them is easy. 
On the other hand, the identification of drugs becomes difficult as time passes. 
Moreover, metabolites and interfering substances increase as the amount of the target 
drug in blood decreases because of metabolism. Therefore, the extraction and 
identification of the drug become difficult. 
It has been known for a long time that drugs are accumulated in hair, as hair -a 
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second-generation sample - became a subject of study [3]. 
As a result, there is a possibility that the existence of the drug can be proven 
because the drug concentration of each part of a hair differs even if time has passed since 
the drug was used. 
Hair consists of the protein keratin. Therefore, the extraction of drug from hair 
becomes difficult compared with samples of the first generation. 
There are chiefly two analytical methods used in the extraction of drugs from hair. 
One is a method of extraction after hair is dissolved with alkali (alkaline digestion 
method). The second is a method of extraction with solvent after the hair is cut with 
scissors as small as possible or pulverised with a mortar or other device (soaking 
method). The first method raises the fear that target analytes might be hydrolysed, and 
the second has the disadvantage that the extraction time becomes long. 
As previously described, the advantage of hair as a second generation sample is to 
be able to prove the existence of the drug even if some time has passed since the drug was 
used. The disadvantage of hair samples is that the amount of sample available for the 
analysis can be very little. 
The fingernail has been ignored for a long time as a sample in the field of forensic 
toxicology. For one reason, fingernails are harder than hairs. Therefore, the fingernail 
cannot be pulverised easily. The method of hydrolysing fingernail samples with alkali 
and the extraction method by cryogenic grinding method have been reported in the 
1990's. 
Therefore, the fingernail can be called the new sample of the third generation when 
considered from a forensic toxicological viewpoint. Drugs in the fingernail, where the 
cryogenic grinding method is applied, can be extracted without hydrolysis of a target drug 
compared with the alkali hydrolysis method. 
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Aims 
The aims of the work carried out in this project were as follows: 
1. To develop and assess improved methods of sample processing, drug extraction and 
analysis for nail samples when used as an alternative matrix in forensic toxicology. 
Earlier work used methods based on alkaline hydrolysis but this is unacceptable in 
many cases because of analyte degradation, especially when drugs of abuse are 
analysed. Both the opiate group and the cocaine alkaloids are easily hydrolysed under 
alkaline conditions. 
2. To apply and evaluate this improved methodology for the analysis of samples relevant 
to the field of forensic toxicology, including nail specimens from controlled drug 
users and from doping steroid users. In this context, nail would be an alternative 
specimen to hair for detection of drug use over a long window of detection period. 
The most commonly abused drugs in the United Kingdom are cannabis and heroin 
and these were selected as the target drug groups in this project. 
3. To investigate instrumental methods of analysis which might be suitable for direct 
analysis of target analytes in the nail matrix and which might enable this type of 
analysis to be carried out with very small samples. If very small samples can be 
directly analysed then nail could be analysed in situ or else nail scrapings rather than 
nail clippings could be analysed. 
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2. Evaluation of Alternative Extraction Procedures for Cannabinoids 
and Opiates in Nail Clippings. 
2.1. Introduction 
In forensic toxicology, if nail is considered as a biological sample, then it belongs to 
the relatively unexplored field of third generation biological samples. 
The first generation samples were urine, blood, and internal organs. The second 
generation samples were hair, sweat and oral fluid (saliva) which had started to be used in 
the 1990's. The chemical compounds taken into nail have been actively researched in the 
fields of cosmetics, environmental medicine and dermatology, to name but a few. 
In the cosmetics field, solvents and other ingredients of manicures (nail polish) have 
chiefly been researched [4,5,6,7]. These investigations concern the permeation of 
chemical compounds from the dorsal nail plate of the nail. For this reason, these studies 
are unrelated to the work described in this thesis. 
In environmental medicine, heavy metals such as arsenic [8], germanium [9], 
selenium [10,11], nickel [12,13,14] and mercury [15] have been studied in the interests 
of environmental pollution or occupational disease. As for cosmetics, the work in this 
thesis has little to do with this research and these fields, because mainly the heavy metals 
have been studied. 
In the dermatological field, in particular toenail onychomycosis, there are a lot of 
papers on the antimycotics in fingernail and toenail, for instance, itraconazole [ 16,17,18], 
ketokonazole [ 18], miconazole [ 19,20], fluconazole [ 18,21 ], and oxiconazole [22]. 
It is reported that the distribution of these antifungal agents to the nail following oral 
administration is prompt. Detailed analytical methods for the drugs are not generally 
described though the extraction methods of antifungal agents can be applied to the 
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extraction of illicit drugs. Moreover, the extraction methods were conventional methods. 
Extremely little research has been done on illicit drugs in nail in the forensic 
toxicological field. The nail is composed of the hard protein that is called keratin, which 
changes the stratum corneum of the skin in the same way as the surface of an animal's 
skin is modified to hair, nail, scale, feather, bill, horn and hoof. Therefore, the extraction 
of drugs from nail is difficult. A detailed review was recently reported by Palmeri et al 
[23]. 
The conventional extraction of analytes in nail is a method involving soaking for a 
long time in solvent after the nail is cut into as small pieces as possible (soaking method) 
[24,25,26,27,28]. This method is subject to several drawbacks including low extraction 
efficiency and possible hydrolysis of the target analytes when exposed to solvents for 
extensive periods of time. The second method is an extraction method after the nail is 
dissolved with an alkaline solution such as sodium hydroxide (alkaline hydrolysis 
method) [29]. In both methods heroin is easily hydrolysed, especially in the latter 
method. Therefore, the presence of morphine and 6-monoacetylmorphine, which are the 
hydrolysis products of heroin, have been used instead to prove the administration of 
heroin. In the same way, the confirmation of 11-nor-A9-tetrahydrocannabinol-9- 
carboxylic acid (A9-THC-000H) and other metabolites is important as it proves the 
consumption and metabolism of b9-tetrahydrocannabinol (A9-THC) in a biological 
system and could help disprove claims of environmental contamination. 
In the present study, cannabinoids, heroin and related opiates have been extracted 
directly from the nail by an extraction method that uses cryogenic grinding. This method 
was carried out under mild conditions, with little hydrolysis of heroin compared to the 
conventional extraction methods. 
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2.2. Experimental 
2.2.1. Nail samples 
Fingernail clippings for cannabinoid analysis were collected with informed consent 
from nine (9) male chronic cannabis smokers participating at the Edinburgh Drug 
Addiction Study. 
The nine volunteers produced their own fingernail clippings using commercially 
available nail clippers under the supervision of a researcher. The nail clippings were 
placed in a transparent plastic bag and transported to the laboratory for analysis. The 
volunteers did not receive any remuneration for providing these specimens. The 
procedures followed were in accordance with the ethical standards of the responsible 
committees on human experimentation (institutional and regional). 
Fingernail and toenail clippings for opioid analysis were collected from 17 people 
at the Glasgow Drug Problem Service in Glasgow (Scotland, U. K. ) after informed 
consent had been obtained from the donors. 
Samples were anonymised but relevant biographical details were noted when the 
clients were interviewed including age, sex, a history of what they have ingested (drug 
types, quantities and frequency of usage on average), an average amount of money spent 
per week on drugs, quantities of methadone a week which were prescribed in their 
methadone substitution programme. 
2.2.2. Reagents 
1) Standards and deuterated standards 
Cannabidiol (CBD), A9-tetrahydrocannabinol (A9-THC), 11-hydroxy-A9-tetra- 
hydrocannabinol (11-OH-A9-THC), and 11-nor-O9-tetrahydrocannabinol-9-carboxylic 
acid (A9-THC-000H) were purchased from Sigma (Saint Louis, USA). 
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A9-tetrahydrocannabinol-d3 (A9-THC-d3) and 11-hydroxy-A9-tetrahydrocannabinol 
-d3 (11-OH-O9-THC-d3) used as internal standards were also purchased from Sigma. 
11-nor-A9-tetrahydrocannabinol-9-carboxylic acid-d3 (A9-THC-COOH-d3) was 
purchased from Radian International (Austin, USA). 
Diacetylmorphine (Diamorphine, heroin) was purchased from Sigma (Saint Louis, 
USA). 
6-monoacetylmorphine (6-MAM), morphine, codeine, dihydrocodeine (DHC), 2- 
ethyl-5-methyl-3,3-diphenylpyrroline (EMDP) and 2-ethylidene-1,5-dimethyl-3,3- 
diphenylpyrroline (EDDP) were purchased from Radian International (Austin, USA). 
6-Acetylcodeine was synthesised by acetylation in which codeine was heated at 60 
°C with acetic anhydride and pyridine as catalyst for 30 min. The purity of the 
synthesised 6-acetylcodeine was confirmed with gas chromatography - mass 
spectrometry (GC-MS). 
Methadone was purchased from High Standard Products Corporation (CA, 
USA). 
Deuterated internal standard compounds of 6-MAM-d3, morphine-d3, codeine-d3, 
methadone-d3 and EDDP-d3 were obtained from Radian International (Austin, USA). 
Stock solutions were purchased from suppliers at a concentration of 100 pg/mL in 
methanol and were diluted to give working standard solutions at a concentration of 
1 µg/mL methanol. 
2) Solvents and reagents 
Methanol was high performance liquid chromatography (HPLC) grade (BDH 
Laboratory Supplies, U. K. ). 2-Propanol was analytical reagent grade (Fischer Science 
International Co., U. K. ). Dichloromethane was from Sigma-Aldrich. Ethyl acetate 
was of analytical reagent grade from Fischer Science International Co. 
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N, O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% of trimethylchloro- 
silane (TMCS) was from Regis Technologies Inc (II, USA). 
Solid phase extraction (SPE) cartridges were Worldwide Monitoring Clean 
Screen cartridges, CSDAU, ZSDAU020 (United Chemical Technologies Inc. Bristol, 
U. K. ). Other solvents and reagents used were all analytical or HPLC grade. 
2.2.3. Instruments 
Cryogenic grinding was carried out using a SPEX CertiPrep Model 6750 Freezer 
Mill from Glen Creston U. K. Ltd. Essentially this device is a ball mill, which is 
operated in an insulated container containing liquid nitrogen. Samples are ground inside 
vials, which are available in both large and micro sizes. The micro-vial set, suitable for 
small samples, was used throughout this study. 
Qualitative and quantitative analysis were carried out using a Thermo Finnigan 
Trace GC-MS equipped with an AS 2000 autosampler and an RTX-5MS column (15 m 
x 0.25 mm i. d.; film thickness 0.25 µm). 
The column temperature was programmed from 150 °C to 300 °C (held for 2 min) 
at 10 °C/min, and the MS detector (70 eV) was operated in the selected ion monitoring 
(SIM) mode or repetitive full scan mode at a source temperature of 220 °C. 
In the latter mode, scans were acquired at approximately 3 scans per sec, giving 
12-18 data points per GC peak in reconstructed ion chromatograms, depending on peak 
width, for quantification of analytes. 
2.2.4. Optimisation of cryogenic grinding method 
Optimisation of the cryogenic grinding cycle (cooling time, number of grinding 
periods and length of each) was performed by Lemos and was not repeated for the work 
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described here. The optimum routine involved three cycles with 1 min pre-cooling period, 
1 min grinding period and 1 min between cycles. 
Six different solvents (acetonitrile, acetone, chloroform, ethyl acetate, hexane and 
methanol) were evaluated as extraction solvents. 
2.2.5. Cleaning of micro-vials for re-use 
To remove any residual contamination of the cryogenic grinder micro-vials before 
they were used again for another sample, the micro-vials were washed well with tapwater. 
Subsequently, they were washed in de-ionised water in a beaker for 15 min with 
ultrasonication. The micro-vials were finally washed with methanol for 15 min with 
ultrasonication. 
To confirm that there was no residual contamination of the micro-vials, 
decontaminated blank nail was used to provide a procedural blank sample. As shown in 
Figure 2.3 (t), no cannabinoids were detected. Similar results were obtained for opioids 
and anabolic steroids, described in subsequent sections. 
Re-use of micro-vials is necessary because they are not disposable items. Routine 
analysis of large numbers of nail samples would best be carried out with multiple sets of 
micro-vials in order to avoid time delays caused by recycling of the vials. 
2.2.6. Sample preparation 
1) Decontamination of nail clippings 
The nail clippings were washed with 10 mL of 0.1 % sodium dodecyl sulfate (SDS) 
for 15 min using ultra-sonication. 
The samples were similarly washed three times with 10 mL of de-ionised water and 
10 mL of methanol, respectively. The methanol wash solutions were preserved for later 
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analysis, in order to establish the complete decontamination of the nails. 
The washed nail clippings were dried at room temperature. The samples were 
approximately divided into half for the cryogenically ground method with liquid 
nitrogen (LN method) and the alkaline hydrolysis method (AH method), respectively. 
Each sample was accurately weighed at each stage of preparation. 
2) Methanolic extraction method with cryogenic grinding 
The washed nail clippings (3.4-109.4 mg) were pulverised with the cryogenic 
grinder under freezing with liquid nitrogen. 
The cryogenic grinder was equipped with a micro-vial set capable of handling small 
weights of samples. The grinding routine involved three cycles with 1-min pre-cooling 
period, 1 min grinding period and 1 min between cycles. The powdered samples were 
rinsed out of the grinding tubes with 10 mL of methanol into clean screw cap tubes and 
the suspensions were sonicated for 15 min. 
Internal standard solutions (50 µL of each of the deuterated cannabinoids or 
deuterated opiates) were added to the methanolic extracts. The methanol extracts were 
centrifuged for 10 min at 3,000 rpm after vortex mixing for 30 sec. The supernatant was 
collected as the liquid nitrogen (LN) portion. 
3) Alkaline hydrolysis method with sodium hydroxide 
The washed nail clippings (3.3-133.0 mg), to which had been added each of the 
internal standards, were hydrolysed with 1 mL of 1M sodium hydroxide solution at 90 °C 
for 30 min in a 15 mL test tube. 
a) Cannabinoids 
The samples were allowed to cool to room temperature and 5 mL of ethyl acetate 
was added to each alkaline hydrolysate. 
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Extraction was performed using a mechanical Rock and Roll extractor (Luckham 
Ltd, U. K. ) for 30 min. The samples were centrifuged for 10 min at 3,000 rpm and the 
ethyl acetate layer was removed from the mixture and used for analysis by GC-MS after 
derivatisation. 
b) Opioids 
After the sample had been cooled, the sample solution pH was adjusted with 1M 
hydrochloric acid using the Accumet Model 10 pH meter within the range pH 6.0-6.5. 
Potassium dihydrogen phosphate buffer solution (0.1 M, 2 mL) was added to the 
hydrolysates prior to SPE extraction. 
The SPE extraction was carried out using an IST Vac/Master device (International 
Sorbent Technology, U. K. ). The SPE cartridge was conditioned with 3 mL of methanol. 
Subsequently, the SPE cartridge was washed with 3 mL of de-ionised water and 1 mL of 
0.1 M potassium dihydrogen phosphate buffer solution. 
The alkaline hydrolysate sample was added to the SPE cartridge at flow of 2 mL/min 
after vortex mixing. 
The SPE cartridge was washed with 2 mL of de-ionised water, 2 mL of 0.1 M 
hydrochloric acid and 3 mL of methanol, respectively. The SPE cartridge was dried for 
10 min under full vacuum. 
Opiates were eluted with 4 mL of dichloromethane/propane-2-ol/ammonium 
hydroxide (78: 20: 2, v/v/v) solution. The eluate was used for the analysis as the sodium 
hydroxide portion. 
4) Derivatisation for GC-MS analyses 
Both the LN portion and AH portions were evaporated to dryness at 60 °C under a 
stream of nitrogen and the residues were derivatised with 50 µL of BSTFA with 1% 
TMCS for 20 min at 70 °C. Derivatised samples were transferred to autosampler vials for 
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GC-MS analysis. 
2.2.7. Gas chromatography -mass spectrometric analyses 
Qualitative and quantitative analysis were carried out with the Finnigan Trace 
GC-MS with AS 2000 autosampler. 
A1 µL aliquot of derivatised analytes were analysed on an RTX-5MS column (15 
mx0.25 mm i. d.; film thickness 0.25 µm) with He (0.9 mL/min) as carrier gas, 
temperature programming from 150 °C to 300 °C (held for 2 min) at 10 °C/min. 
Interface and ion source temperature, detector voltage, emission current were 250 °C, 
200 °C, 500 V and 350 µA, respectively and the instrument was operated in the EI+ 
selected ion monitoring (SIM) mode with an electron energy of 70 eV. 
2.2.8. Quantitation of cannabinoids in nail extracts 
1) Preparation of standard samples for calibration curve 
All standard cannabinoid stock solutions were prepared at a concentration of 1 
mg/L in methanol. 
For each cannabinoid analysed, a series of solutions was prepared in order to 
construct a standard calibration curve. In small test tubes 10,25,50,100 and 250 µL of 
each cannabinoid standard were added together with 50 pL of internal standard solution. 
These samples were then derivatised and analysed by GC-MS in order to produce 
proper calibration curves. 
2) Calibration curve 
The quantitative analysis of each cannabinoid used the SIM mode of GC-MS. One 
pL of each standard solution was injected into the GC-MS and the peak area ratio of the 
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sample to the internal standard sample was used for the preparation of the calibration 
curve. 
3) Fragment ions used for the SIM mode 
Table 2.1 shows the selected ions and retention times used for the identification 
and quantification of the cannabinoids. 
CBD (m/z 390) and A9-THC (m/z 371,386) used A9-THC-d3 (m! z 389,374) as 
internal standard. 11-OH-O9-THC (m/z 371,474) used 11-OH-A9-THC-d3 (Wz 374) as 
internal standard. Finally, E9-THC-000H (m/z 371,473,488) used O9-THC-COOH-d3 
(m/z 374) as internal standard. 
2.2.9. Quantitation of opioids in nail extracts 
1) Preparation of standard samples for calibration curve 
All stock standard opiates and methadone were prepared at concentrations of 1 mg/L 
with methanol and diluted prior to use. Each of the standard sample solutions prepared 
was separately collected in small test tubes in aliquots of 5,15,50,100 and 250 µL, 
respectively. Internal standard solutions (50 µL) were added to each test tube at the same 
time. Unextracted standards were used as it was not possible to introduce drugs into the 
nail matrix. These samples were derivatised and prepared for the calibration curves by 
the same method as the sample preparation from the nail. 
2) Calibration curve 
The quantitative analysis of each drug used SIM mode of GC-MS. One (1) µL of 
each of the standard solutions at concentrations of 0.1,0.3,1.0,2.0 and 5.0 mg/L were 
introduced into GC-MS respectively. The peak area ratios of the drug standards to 
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internal standards were used for the preparation of the calibration curve. 
3) Fragment ions used for the SIM mode 
The quantified compounds and selected ions were as shown in Table 2.1. 
Methadone (m/z 294) used methadone-d3 (m/z 297) as an internal standard. Codeine (m/z 
371), DHC (mz 373), and 6-acetylcodeine (m/z 341) used codeine-d3 (nVz 374) as an 
internal standard, respectively. Morphine (m/z 429) used morphine-dj (m/z 432) as an 
internal standard. Heroin (m/z 327) and 6-MAM (m/z 399) used 6-MAM-d3 (m/z 402) as 
an internal standard. 
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Table 2.1. Retention times and selected ions for GC-MS analysis of nail extracts 
No. Compound name 
R. Time 
(min) 
Selected Ions 
(m/i) MW 
TMS 
(number) 
1 CBD 7.91 301,337,390 488 di 
2 A9-THC-d3 8.81 374,3ß2 389 mono 
3 09-THC 8.83 371, R6 386 mono 
4 A9-THC-COOH-d3 11.79 374 491 di 
5 09-THC-000H 11.81 371,473 488 di 
6 11-OH-THC-d3 10.78 374 477 di 
7 11-OH-THC 10.80 371,372,474 474 di 
8 EMDP 5.36 208,193 263 0 
9 EDDP-d3 6.14 2B, 279 280 0 
10 EDDP 6.17 ZZZ, 276 277 0 
11 Methadone-d3 7.06 297 312 0 
12 Methadone 7.08 294 309 0 
13 Dihydrocodeine 9.01 3Z 373 mono 
14 Codeine-d3 9.59 IZ4,346 374 mono 
15 Codeine 9.61 M, 343 371 mono 
16 Morphine-d3 10.01 432,417 432 di 
17 Morphine 10.03 42,414 429 di 
18 6-Acetylcodeine 10.17 X91,282 341 0 
19 6-MAM-d3 10.53 4 2,343 402 mono 
20 6-MAM 10.54 . 22,340 
399 mono 
21 Heroin 11.14 327930 369 0 
22 Papaverine 12.64 N/Q 339 0 
23 Noscapine 14.86 N/Q 413 0 
Notes: N/Q = Not quantified, TMS (number) = number of trimethylsilyl group. 
Bold, italic and underline = molecular ion (m/z). 
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2.3. Results and Discussion 
2.3.1. Optimisation of the cryogenic grinding method 
The extraction method of drugs in nail used Lemos's method [30]. The conditions 
with respect to the time needed to cool the grinder with liquid nitrogen and time intervals 
to pulverise the frozen nail with the cryogenic grinder were examined respectively. As a 
result, the conditions that were found to be effective were a cooling time of 1 min and 
grinding time of 2 min., with the cycle being repeated twice. 
The electron probe X-ray microanalyser (EPXMA) was used to compare the size of 
the particulates in the powdered nail samples after extraction with cryogenic grinding. 
The minimum grain size in a powdered nail sample had a diameter of less than about 0.6 
µm (Figures 2.1 and 2.2). 
The kind of solvent used to extract drugs from the pulverised nail was also 
examined. The solvents tested were acetone, acetonitrile, chloroform, ethyl acetate, 
hexane, and methanol. Methanol was selected based on the low background interference 
obtained, the easiness of the solvent to handle and the solubility of the analytes (Figures 
2.3a-f). 
Impurities detected from methanol blank were mainly phthalate esters (dibutyl 
(DBP) and dioctyl (DOP)), aliphatic fatty acid esters (palmitic and stearic) and butylated 
hydroxytoluene (BHT). These components originate chiefly in plastic additives that 
contaminate the environment. 
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Figure 2.1. Pulverised nail after extraction with ethyl acetate 
Figure 2.2. Pulverised nail after extraction with ethyl acetate 
(Courtesy of Mr. Syuji Saitoh, NRIPS, Japan). 
The diameter of a nail particle is less than about 0.6 µm. 
(Courtesy of Mr. Syuji Saitoh, NRIPS, Japan). 
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2.3.2. Cannabinoid analysis 
The alkaline hydrolysis of the nail corresponded to Lemos's method [31]. In this 
method, nail clippings dissolved promptly in alkaline solution, and a pale yellow, 
transparent liquid was easily obtained. 
CBD, 11-OH-09-THC and A9-THC were identified and quantified in both the 
cryogenic grinding (LN) and alkaline hydrolysis (AH) portions. 
Moreover, A9-THC-000H was detected in the LN portion [Figures 2.4-2.6]. All of 
these compounds were determined in the full scanning mode except in the case of 11- 
OH-O9-THC and A9-THC-000H where the use of the SIM mode was necessary. All 
compounds eluted within the range of 7.5 to 12.0 min as shown in Table 2.1. 
The number of peaks in the chromatogram for the AH portion was less than for the 
LN portion. A possible reason for this is that the nail sample is hydrolysed under extreme 
alkaline conditions and more endogenous materials are subsequently recovered in the 
extract. Figure 2.7 summarises the compounds detected in each specimen using the two 
methods of extraction. 
The calibration curves prepared showed linearity from 0.2 ng to 5.0 ng for all 
cannabinoids. Figure 2.7 shows the concentrations of cannabinoids per one milligram of 
nail in each of the case samples from the Edinburgh Drug Addiction Study (EDAS). 
The concentration of e9-THC was similar for our specimens in both the LN and the 
AH portions. A9-THC-000H could not be detected by the AH method, though this 
cannabinoid was clearly identified and quantified by the LN method. The reason is that 
A9-THC-000H is readily soluble in aqueous alkali and the recovery of this analyte is 
low. 
Earlier work had shown that pH adjustment prior to solvent extraction permitted 
some recovery of the metabolite but at the expense of interference from co-extracted 
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interferences. Also of interest was the presence of cannabidiol at concentrations, on 
average, higher than either tetrahydrocannabinol or its carboxylic metabolite. Figure 2.8 
shows a comparison of the average values for the cannabinoids obtained by each method. 
Various authors have reported the presence of minor cannabinoid components in 
seized cannabis or biological samples, such as A8-THC [32], cannabichromene [33], 
cannabigerol [32,33] and propyl [34,35] homologues of A9-THC [36,37,38]. None of 
these minor components were detected in either the cryogenic grinding or alkaline 
hydrolysis portion. 
It can be concluded that nail analysis is useful for monitoring of past cannabis use 
and that for this purpose, the hydrolysis and cryogenic grinding methods produce 
comparable results. However, cryogenic grinding has some advantages. It is a milder 
chemical treatment, suitable for drug screening of alkali-sensitive substances, and, as 
shown in this study, 09-THC-000H can be detected. The applicability of this technique 
was subsequently evaluated for opioids in nail. 
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In the AH portion, THC-COOH is not detected because of an extraction at alkaline 
pH. In general, in the AH portion, the concentration of cannabidiol (CBD) was higher 
than in the LN portion except sample No. 1. 
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2.3.3. Opioid analysis 
As for cannabinoids, alkaline hydrolysis according to Lemos's method [31] 
resulted in a pale yellow transparent liquid. 
Clean Screen SPE cartridges were able to extract a wide-range of drugs including 
opiates and methadone from this solution. 
1) Derivatisation of analytes 
Opiates can be analysed by GC-MS without derivatisation, even though the samples 
have hydroxyl or amino functional groups. 
However, it was found that during initial GC-MS analysis of nail extracts, the 
analytes were detected as TMS derivatives even though the samples were not treated with 
BSTFA, because the GC-MS used had already been contaminated with the silylation 
reagent and an on-column reaction occurred with the residual reagent. Therefore, all 
extracts were subsequently analysed by GC-MS after reaction with BSTFA reagent. 
2) Qualitative and quantitative analyses of the GC-MS 
a) Qualitative analysis 
The opium alkaloids morphine, codeine, noscapine and papaverine and the opioid 
methadone were detected in both LN and AH portions. Moreover, heroin, 6-MAM and 
6-acetylcodeine were only detected in the LN portion [Figures 2.9 and 2.10]. 
All compounds eluted within the range of 5-15 min, as shown in Table 2.1. The 
number of peaks of the AH portion was less than that of the LN portion [Figures 2.11 and 
2.12]. The reason for this is that the sample is purified by SPE after hydrolysis in the AH 
method. 
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Figure 2.9. Mass chromatograms of sample number LN03 (LN portion) 
Mass chromatograms of Codeine (mz 371), Morphine (m/z 429), 6-Acetylcodeine 
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Figure 2.10. Mass chromatograms for sample number LN03 (LN portion) 
Mass chromatograms of 6-MAM (mz 399), Heroin (m/z 369), Papaverine (m/z 
338), and Noscapine (m/z 220). 
Retention times were 10.54,11.14,12.63, and 14.86 min, respectively. 
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Figure 2.11. GC-MS analysis of sample number AH03 (AH portion) 
Mass chromatograms (m/z 429 for Morphine-di-TMS, m/z 371 for Codeine-mono- 
TMS). Retention times were 9.62 (Codeine-mono-TMS) and 10.03 min (Morphine-di- 
TMS), respectively (upper). Mass spectrum of Codeine-mono-TMS (lower). 
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Table 2.1 shows retention times for the detected compounds. These compounds 
could be determined in the full scanning mode. 
Heroin, 6-MAM and 6-acetylcodeine with substituent groups at the C6-position of 
the morphine structure [Figure 2.13] could not be detected by the AH method, though 
these opiates could be identified with the LN method. 
The reason is that the heroin is easily hydrolysed by alkaline conditions, which is a 
problem in the conventional alkaline hydrolysis method [Figure 2.14]. By contrast, 
opiates having substituent groups at the C6-position were determined easily with the LN 
method. 
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b) Quantitative analysis 
The calibration curves showed straight lines from 0.1 ng to 5.0 ng for methadone 
and all opiates. 
Correlation coefficients for heroin, 6-MAM, 6-acetylcodeine, morphine, DHC, and 
codeine were 0.9958,0.9985,0.9995,0.9958,0.9937 and 0.9995, respectively [Figure 
2.15]. The calibration curve for codeine at low concentrations, from 0.025 to 0.10 ng, 
was also measured and showed a calibration curve with a particularly good linear 
correlation coefficient. It was concluded that little decomposition of the sample occurred, 
because the unstable morphine structure at the C3-position is occupied by the alkyl 
(methyl) ether group [Figure 2.13]. 
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Figure 2.15. Calibration curve for Codeine-mono-TMS 
Table 2.2 shows the concentration of opiates per one milligram in weight of the nail 
in the same. 
In the AH portion, the morphine concentration was very high compared with the LN 
portion. This suggests that morphine formed by hydrolysis of heroin and 6-MAM has 
increased the apparent morphine concentration in the AH portion [Figure 2.14]. 
Similarly, the codeine concentration was higher in the AH portion because of 
hydrolysis of 6-acetylcodeine. 
In general, it is not yet possible to attempt any correlation between the dose of 
administered opioid and the subsequent concentration of the opioid in nail. The doses 
administered by the donors of nail samples used in this study are not known. Controlled 
dose studies will be required in future to allow this type of correlation to be studied. 
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3) Consideration of individual opioids 
a) Methadone and related compounds 
Methadone is a drug supplied as a replacement for heroin to heroin abusers. 
Methadone was detected in 12 nail samples out of the 17 obtained from donors at the 
Glasgow Drug Problem Service. EDDP and EMDP are metabolites of methadone. 
The quantification of these compounds was attempted at the same time as 
methadone, using deuterated internal standard, EDDP-dj but the chromatographic peak 
shape was poor and no useful results were obtained. 
b) DHC 
As shown in Figure 2.13, codeine has a methyl ether substituent group at the C3- 
hydroxyl position. In DHC, the double bond in codeine between the C7- and C8- 
positions is saturated with hydrogen. DHC is known as a strong anti-tussive semi- 
synthetic morphinoid drug and is restricted by the law. 
Because DHC is frequently detected in the analysis of opiates in biological samples 
[39,40,41,42,43,44], it was decided to include it in the list of target analytes in nail. 
During quantitative analysis using the SIM mode, DHC was quantified using the 
chromatograms for m/z 373,358, and 315. However, peaks at the retention time for DHC 
in the sample extracts had different relative intensity ratios compared to those of the 
qualifier ions in the DHC standard. Also, DHC was not detected easily in the analysis by 
full scan mode, though peaks were detected at the correct retention time in the SIM mode 
analysis. 
Therefore, DHC was considered not to have been reliably detected, because it is a 
semi-synthetic drug and the quantitative and qualitative analyses were performed without 
addition of DHC-d3 as an internal standard, which would have assisted in confirming the 
presence of DHC. 
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c) Heroin, 6-MAM and morphine 
Heroin, 6-MAM and morphine were identified and quantified in the LN portions as 
shown in Figures 2.9-2.10 and Figures 2.16-2.18. However, they were not detected in 
the AH portion, in which only morphine was detected [Figures 2.11-2.12]. 
In general, it is difficult to identify heroin directly in biological samples (urine, 
blood, internal organs and hair etc. ). The acetyl group at the C3-position of heroin is 
easily hydrolysed during sample preparation and/or metabolism in human body and the 
heroin becomes 6-MAM (Figure 2.14). Therefore, to prove the existence of heroin in 
biological samples, 6-MAM was identified as a biomarker of heroin [45,46,47,48]. 
Similarly, the acetyl group at the C6-position of 6-MAM is easily hydrolysed under 
alkaline conditions and 6-MAM becomes morphine. Therefore, the detection of heroin 
was quite impossible in the conventional alkaline hydrolysis method for nail samples. 
Heroin is detected only by using the conventional soaking method when the analyte 
concentration is high or rapid sample preparation was performed to avoid solvolysis of 
the analyte. 
Because the LN method was a soft extraction procedure, heroin could be directly 
detected in nail for the first time. 
d) 6-Acetylcodeine and codeine as specific markers for illicit heroin 
In the LN portion, 6-acetylcodeine and codeine were both detected (Figures 2.9, 
2.19,2.20). However, 6-acetylcodeine could not be detected with the alkaline hydrolysis 
method, as expected. The reason is that 6-acetylcodeine converts to codeine by alkaline 
hydrolysis [Figure 2.14]. 
Though identification and quantification of morphine and its derivatives were 
described above, the correlation between the LN and AH methods were considered. 
38 
LN03fs#977 RT: 11.14 AV: 1 SB: 2 11.13,11.18 NL: 4.66E5 
T: {0,0} +c El det=500.00 Full ms 148.00-588.001 
100- 
go- 
26f 
80 
70 
Re 215.0 
latg0 
ve 
Ab 
un50 81.1 
da 
nc40 
162.2 e 
30 70 2 
942 124.2 267.2 
115,0 266.1- 
20 144.1 211.2 
226.2 
10- 1,238.2 
0 ýAl . 1111 
1. 
- 
LN03fs 1905 RT: 10.54 AV. 1 NL: 5.31E6 
T: {0,0}. c EI det=500.00 Ful ms 148.00.588.001 
1 73.0 
204.2 
162.0 
59.1 81.0 124.1 
70-ý 
146.0 
94.1 
M+ 399 287.1 
340.1 
TI 
399.2 
28 .1 
ý7.2 
266.1 324.2 
3 
1216.0 
246.2 
-{ 11 
.0 
1662 1 
i 
,. 
I 11 
203.1 11 229.1 , 
356.2 
.2 473.4 
512.3 
160 190 260 250 360 350 400 450 500 550 
m/z 
Figure 2.17. Mass spectrum of 6-MAM-mono-TMS 
(Retention time 10.54 min) 
Figure 2.16. Mass spectrum of Heroin (Retention time 11.41 min) 
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Table 2.3. Concentration of each opioid in 
nail sample No. 3 (ng/mg nail) 
Opioid 
Name 
LN 
ng/mg 
AH 
ng/mg 
Heroin 1.14 0.00 
6-MAM 15.91 0.00 
6-AcCodeine 1.97 0.00 
Morphine 7.62 25.37 
Codeine 0.86 7.66 
Methadone 0.09 0.50 
Notes: LN = liquid nitrogen method. AH = alkaline hydrolysis method. 
When the total number of nanomoles of morphine and its derivatives in each LN and 
AH portion were calculated, the number in the LN portion was due to morphine (7.62 
ng/MW 285) + heroin (1.14 ng/MW 369) + 6-MAM (15.91 ng/MW 327) = 0.079. 
Similarly, the nanomoles of morphine in the AH portion from morphine alone (25.37 
ng/MW 285) = 0.079. As a result, molar content of morphine determined by the LN and 
the AH methods was almost the same value [Table 2.3]. Therefore, it can be considered 
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that the LN method does not have any recovery problem in the extraction compared with 
the AH method. 
There are many reports in which 6-acetylcodeine is identified as the major impurity 
in seized street heroin [49,50,51,52,53,54,55,56,57,58,59,60], therefore 6- 
acetylcodeine has been used as a marker of illicit heroin. 
Papaverine, noscapine, thebaine are also well known as major impurities in seized 
heroin. By contrast, very few reports have been published concerning 6-acetylcodeine in 
biological samples such as hair [61,62] or urine [63,64] and there is no previous report 
for nail at all. 
In the analysis of hair, it was reported that 6-acetylcodeine was not suitable as a 
biomarker of illicit heroin use as the concentration in hair is low [65]. In future, 6- 
acetylcodeine will be able to serve as a biomarker of illicit heroin in nail samples if a lot 
of analytical data were accumulated using either new methods or the LN method which 
was used in this work. 
e) Papaverine, noscapine, and thebaine as major impurities in illicit heroin. 
Both papaverine and noscapine were detected in the LN and the AH portions though 
thebaine could not be detected [Figures 2.10,2.21-2.22]. This is the first report until the 
present that papaverine and the noscapine were detected in biological samples along with 
heroin. 
According to the Merck Index (12th edition, drug number 6986), papaverine and 
noscapine, which have the isoquinoline structure, are minor components in opium. By 
contrast, another minor component, thebaine, has the morphinan structure. These minor 
components nevertheless constitute the quantitatively largest impurities. The number and 
the composition of the alkaloids are described as follows: about 20 alkaloids, constituting 
42 
about 25% of the opium; meconic acid, some lactic and sulfuric acids, sugar, resinous and 
waxy-like substances; 12-25% water. 
Morphine is most important alkaloid and occurs to the extent of 10-16%, noscapine 
4-8%, codeine 0.8-2.5%, papaverine 0.5-2.5% and thebaine 0.5-2%. 
The question arises with respect to how many types of alkaloid in opium are known 
at this moment in time, though the number of alkaloids has been described as 20 kinds or 
more. More than 100 types of alkaloid exist in opium [66]. However, the best known 
alkaloids of interest might be the 20 compounds listed in Table 2.4. Actually, the number 
of opium components reported in articles using instrumental analysis is no more than 
about ten types. 
Illicit heroin mostly- contains only major impurities. There are many reports 
concerning the papaverine and the noscapine contained in illicit heroin [50,53,57,59,67, 
68,69,70,71,72,73,74]. However, few articles have been published which report on 
the thebaine content of opium. 
However, no previous studies have been reported concerning the detection of 
papaverine and noscapine along with illicit heroin in biological samples. Moreover, there 
have been no previous studies in which papaverine and noscapine were detected in nail. 
Studies in the literature concerning papaverine and the noscapine in biological 
samples do not relate these compounds to heroin use [75,76]. 
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Table 2.4. Opium alkaloids and their discoverers 
k4) jrum science of u sates ,r osniyuxi icninoe kinenseisy a, japan, ty5L), p. ou 
St t Alk l id 
Discoverer 
No. ruc ure a o 
Group Name Mol. Formular MW Name Year 
1 Morphine C17H19NO3 285.33 C. Derosne 1804 
2 Pseudomorph. (C17H18NO3)2 568.67 J. Pelletier 1903 
3 Codeine C18H21N03 299.36 M. Robiquet 1832 
4 
Morphinan 
Thebaine C19H21N03 311.37 
J. Pelletier, 
Thiboumery 
1832 
5 Neopine C18H21NO3 299.36 T. & H. Smith 1911 
6 Porphyroxine C19H23NO4 329.38 J. N. Rakshit 1919 
7 Papaverine C20H21N04 339.38 G Merck 1848 
8 Pseudopapav. -- -------------- -------- O. Hesse 1903 
9 Codamine C20H25NO4 343.41 O. Hesse 1870 
10 Benzyl- Laudanine C20H25NO4 343.41 O. Hesse 1870 
11 isoquinoline Laudanosine C21H27NO4 357.43 O. Hesse 1871 
12 Papaveraldine C20Hl9NO5 353.36 T. & H. Smith 1893 
13 Laudanidine C20H25NO4 343.43 O. Hesse 1894 
14 1-Laudanidine C20H25NO4 343.43 E. Kauder 1890 
15 Noscapine C22H23NO7 413.43 C. Derosne 1804 
16 Narceine C23H27NO8 445.47 J. Pelletier 1832 
17 Phthalide- Gnoscopine C22H23NO7 413.43 O. Hesse 1871 
18 
isoquinoline 
Oxynarcotine C22H25N08 431.44 
GH. Beckett, 
C. R. A. Wright 
1875 
19 Narcotline C21H21N07 399.39 Wrede 1937 
20 Cryptopine 
Protopine 
C21H23NO5 369.40 T. & H. Smith 1864 
21 Protopine C20H19NO5 353.36 O. Hesse 1871 
22 
Tetrahydro- 
Hydrocotamine 
isoquinoline 
C12H15N03 221.25 O. Hesse 1871 
23 Rheadine C21H21NO6 383.39 O. Hesse 1866 
24 Aporeine C18H17NO2 343.43 Pavesi 1907 
25 Lantopine 
Other ---------------- -------- 
O. Hesse 1870 
26 Meconidine ---------------- -------- O. Hesse 1870 
27 Papaveramine ---------------- -------- O. Hesse 1903 
28 Sanguinarine C20Hl4NO4 332.34 Schmidt 1893 
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Table 2.4. (b) from Matthias Unger et al., J. Chromatogr., A 767 (1997) 263-276 
No. 
Group 
Name 
Molecular 
MW 
Discoverer 
(Structure) Formular Name Year 
2 Coptisine-CI C19H14CIN04 355.80 Kitasato 1927 
3 Berberine-HC1 C20H18CIN04 299.36 
Wasicky 
Joachimowitz 
1917 
4 Palmatine C21H22N04 352.41 Feist, Dschu 1925 
5 Chelidonine C20Hl9NO5 353.37 
6 Columbamine C20H20NO4 339.40 
7 Jatrorrhizine C20H21NO4 323.36 
8 Stylopine C19H17N04 323.36 
9 Conadine C20H21NO4 339.40 
10 Scoulerine C19H21N04 327.39 
11 Norharmane CI1H8N2 168.21 
12 Harman C 12H l ON2 182.22 
13 
ß-Carboline 
Harmaline C13H14N20 214.27 
14 Harmine C13H12N20 212.25 
15 Harmalol C12H12N20 200.24 
16 Harmol C12HION20 198.23 
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t) Miscellaneous minor impurities in illicit heroin. 
The minor impurities in illicit heroin such as thebaol, acetylthebaol, hydrocotarnine 
and 3,6-dimethoxyphenanthrene-4,5-epoxide were not detected in either the LN or AH 
portions, though thebaol [77,78], acetylthebaol [78,79,80,81], hydrocotarnine [82] and 
3,6-dimethoxyphenanthrene-4,5-epoxide [77] have been reported as minor impurities in 
seized illicit heroin. 
g) Normorphine and norcodeine as secondary metabolites of illicit heroin 
Normorphine and norcodeine were not detected in either the LN or AH portions. 
Sample number 3 contained large amounts of morphine and codeine and it was therefore 
presumed that it would contain the metabolites (normorphine and norcodeine) if these 
were formed, but neither compound was detected. 
Many opium alkaloids were targeted in this GC-MS analysis. However, these 
compounds could not be detected easily, because analytical conditions had not settled for 
the analysis of the secondary metabolites. 
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2.4. Conclusions 
THC and its metabolites 11-OH-THC and THC-COOH as well as CBD were 
detected and quantified in nail clippings from cannabis users using the cryogenic grinding 
method followed by GC-MS analysis. By contrast, THC-COOH was not readily detected 
in nail clippings by alkaline hydrolysis. Extraction of cannabinoids from nail clippings 
using the cryogenic grinding method was found to be a simple procedure that could be 
applied effectively to a wide range of analytes without the need to consider their different 
polarities. 
Similarly, heroin and the related opiates in nail clippings were extracted with the 
cryogenic grinding method and the results were evaluated in comparison with the 
conventional alkaline hydrolysis extraction method. Both the AH and LN methods gave 
the same total concentration of morphine (0.079 nano-moles/milligram of nail), when the 
result of the analyses were expressed as equivalents of morphine. 
Heroin, 6-MAM, and acetylcodeine could not be detected by the conventional 
alkaline hydrolysis method, but could be detected with the cryogenic grinding method. In 
addition, papaverine and noscapine were identified together with heroin from nail 
samples for the first time. This is also the first report in which these analytes have been 
analysed by GC-MS at the same time in any biological sample. 
6-acetylcodeine, having an acetyl group at the C6-position of the morphinan 
structure, and opium alkaloids (papaverine, noscapine etc. ) might be used in the near 
future as biomarkers for the administration of impure street heroin. 
In contrast, only morphine and codeine were identified and quantified with the 
alkaline hydrolysis method. These opioids could also be determined with the cryogenic 
grinding method. 
Heroin is a synthetic opioid compound having acetyl groups at both the C3- and 
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C6-positions of the morphine structure. The acetyl substituent group of heroin at the 
C6-position is easily hydrolysed, and heroin is converted to 6-MAM in the soaking 
method, which uses solvent exposure over a relatively long period of time. Moreover, 
both substituent groups are completely hydrolysed to produce morphine in the alkaline 
hydrolysis method. 
In summary, cryogenic grinding has been shown to be a suitable sample preparation 
method for the routine analysis of nail specimens, which can therefore be used as an 
alternative analytical sample in cases of forensic toxicological interest. The cryogenic 
grinding method has significant advantages over the alkaline hydrolysis method with 
respect to sample degradation and extends the range of accessible analytes to include 
several markers of heroin use. The practical application of the method requires the use of 
liquid nitrogen and the provision of multiple sets of micro-vials for the grinder, if large 
numbers of samples are to be analysed, but these costs are offset by the improved utility 
of the method. The use of nail, as for hair samples, extends the potential window of 
detection of drugs beyond what is possible with more conventional samples such as blood 
and urine. However, unlike hair analysis, analysis of drugs in nail is a relatively new 
subject and much additional work is required to establish the extent of its usefulness in 
forensic toxicology. 
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3. Analysis of Anabolic Steroids in Nail Clippings from Steroid Users 
3.1. Introduction 
3.1.1. Doping steroids 
It is difficult to define doping steroid in a single phrase. In the dictionary, dope 
means a drug used to enhance the performance of an athlete, racehorse, or greyhound 
[83]. 
According to the dictionary of the Microsoft Encarta [84], the word dope is 
probably derived from the Dutch word dop, the name of an alcoholic beverage made of 
grape skins used by Zulu warriors in order to enhance their prowess in battle [85]. The 
term became current around the turn of the 20th century, originally referring to illegal 
drugging of racehorses. The practice of enhancing performance through foreign 
substances or other artificial means, however, is as old as competitive sport itself. 
It is surmised that "dope" naturally became synonymous with various kinds of 
drugs, and came to be used in the context of playing a game or sport illegally. A doping 
steroid should meet at least the following three requirements: 
1) a doping steroid must have basically the chemical structure of testosterone. 
2) a doping steroid must be an anabolic androgenic steroid (AAS). 
3) a doping steroid must be registered in the prohibited list of the World Anti-Doping 
Agency (WADA). 
3.1.2. Testosterone 
Doping steroids comprise testosterone (17ß-hydroxyandrost-4-en-3-one, C19H2802 
= 288.43) and its related steroid compounds with the testosterone nucleus, shown in 
Figure 3.1. 
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Figure 3.1. Chemical structure and numbering system of Testosterone 
Testosterone is an anabolic steroid, which forms the basic framework of doping 
steroids. Testosterone is described according to Martindale [86] as follows: 
"Testosterone is the main androgenic hormone formed in the interstitial (Leydig) 
cells of the testes. A small proportion of circulating testosterone is also derived from the 
metabolism of less potent androgens secreted by the adrenal cortex and ovaries. " 
In many target tissues testosterone is then converted to the more active hormone, 
dihydrotestosterone (DHT) by 5a-reductase. Some testosterone also undergoes 
peripheral conversion to estradiol. 
Testosterone controls the development and maintenance of the male sex organs and 
the male secondary sex characteristics. It also produces systematic anabolic effects, such 
as increased retention of nitrogen, calcium, sodium, potassium, chloride and phosphate. 
This leads to an increase in water retention and bone growth. The skin becomes 
more vascular and less fatty and erythropoiesis is increased. The androgens generally 
possess anabolic activity and were formerly used to increase weight in patients suffering 
from emaciation or debilitating diseas es but their effectiveness was doubtful. The 
anabolic steroids were developed in order to enhance the ability to build proteins and 
diminish the virilising and masculinising effects of the natural androgens, but all 
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anabolics retain some androgenic activity [87]. The anabolic steroids have, like the 
androgens, been used in an attempt to produce weight gain in cachexia (weakness and 
wasting of the body due to severe chronic illness) and wasting diseases. 
Anabolic androgenic steroids have been subject to much misuse and abuse by 
athletes, sports persons and body builders in an attempt to increase muscle mass and 
body-weight but such use cannot be justified. 
As shown in the description in Martindale [86], the illegal abuse of testosterone 
and related compounds is more prominent than normal use. However, only doping 
steroids (illegal use of anabolic steroids) in humans will be the subject described here. 
3.1.3. Biosynthesis and metabolism of testosterone 
As indicated in Martindale [86], testosterone is formed in the interstitial (Leydig) 
cells of the testes. The starting point for its biosynthesis is cholesterol, which itself is 
derived from the terpenoid precursor, squalene. In general, cholesterol is synthesised in 
the body by the acetyl CoA metabolic pathway as shown in Figures 3.2-3-4. 
The intermediate C21 steroid, pregnenolone, becomes testosterone through various 
metabolic pathways. Estradiol, which is a type of female hormone, is generated by 
metabolism of testosterone in vivo, though testosterone is considered to be a male 
hormone. Is this a mysterious phenomenon of life? In fact both male and female produce 
both sets of steroids, but usually in different amounts. 
When steroid extraction from biological samples and analysis is carried out a 
complex mixture of Cl,, C, 9 and C21 steroids is encountered. For this reason, estrogens 
and progestagens as well as the metabolites of anabolic steroids were included in this 
study. 
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Figure 3.2. Biosynthesis and metabolism of Testosterone 
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3.1.4. World Anti Doping Agency 
World Anti-Doping Agency (WADA) is an international organisation concerned 
with the control of doping in sport. WADA was formed in November 1999, as a result of 
an initiative of the International Olympic Committee (IOC), to support and promote 
fundamental values in sport. 
According to the WADA Internet web site [85], a large number of prohibited 
medical substances were found by police in a raid during the Tour de France in 1998. 
The scandal led to a major reappraisal of the role of public authorities in anti-doping 
affairs. 
The Tour de France scandal highlighted the need for an independent international 
agency, which would set unified standards for anti-doping work and co-ordinate the 
efforts of sports organisations and public authorities. 
The World Conference on Doping in Sport was held in Lausanne in February 1999 
and subsequently the World Anti-Doping Agency was established in Lausanne on 10 
November 1999. 
The WADA doping control code is revised every year [Table 3.1]. Nevertheless, 
the abuse of doping steroids in the sporting world has been a regular topic. Eight kinds of 
prohibited substances including stimulants, narcotics, cannabinoids, peptide hormones, 
beta-2-agonist, agents with anti-estrogenic activity, masking agents, and 
glucocorticosteroids as well as anabolic steroids are regulated under the WADA code. 
The controlled steroids and related compounds in the WADA doping steroid group 
basically include about 40 kinds as of 2004. 
Doping control by various sports groups that are signatory subsidiaries of WADA 
set an original doping restriction in accordance with this WADA code. For instance, the 
content is almost the same in the United States of America and Britain as shown in the 
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United States Anti-Doping Agency (USADA) guide list [Table 3.2] and the list of new 
controls in the supply of anabolic steroids issued by the Home Office in the United 
Kingdom [Table 3.3]. 
Similarly, the list of controlled substances in the steroid group used in sporting 
events hardly differs from the WADA charter. Therefore, it is not an exaggeration to say 
that the content of doping control in various sports groups is the same as the content of the 
WADA code. 
3.1.5. Types of doping steroids 
A review of doping steroids based on related books, journals and Internet Web 
sites gave a collection of about 600 types of steroid, including anabolic steroids and their 
related metabolites as well as progestagens and estrogens. 
Roughly speaking, when doping steroids are analysed, about 50 or 60 substances 
should be considered. The reason is that a number of endogenous anabolic steroids are 
added to the number of exogenous (synthetic) anabolic steroids for which WADA 
provides (Table 3.1 and Table 3.4). 
3.1.6. Contexts in which doping steroids are used 
As time went on, dope came to be used illegally not only in man but also in various 
animals. The abuse of doping steroids has been reported in horseracing [88,89,90,91, 
92,93,94], dog racing [95], and pigeon racing [96], amongst others. No papers have 
been published dealing with abuse of doping steroids in blood sport games such as bull, 
dog and cockfighting. However, the illegal use of dope is easily speculated in gambling 
sports that use these animals. 
Serious problems concerning illegal use of doping steroids result from their use in 
57 
various human sports and as growth promoters for livestock and poultry [97,98,99,100, 
101,102,103,104,105]. Additionally, there are data regarding naturally occurring 
steroids in fish, including sex hormones [105,106]. 
Humans have indirectly taken synthetic anabolic steroids into their body from meat, 
chicken and fish polluted with anabolic steroids, though they did not know of the 
presence of the steroids in these foodstuffs. 
Obtaining doping steroids is actually difficult because of legal restrictions. 
However, the spread of Internet Web sites has promoted illegal acquisition of doping 
steroids. Therefore, doping steroids have been increasingly abused nowadays. 
3.1.7. Analytical samples 
The analytical specimens for doping steroids have included internal organs, blood 
and urine as conventional biological samples. 
There are innumerable theses and publications concerning these samples. As 
interesting examples, studies of faeces [96,107,108] and hair of domestic animals [99, 
109,110,111 ] were reported as samples used for the detection of promoters in livestock. 
In the human, hair has been used as a substitute for these biological samples [112, 
113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130, 
131]. 
However, hair samples have not yet been officially adopted in doping control in 
regular sport. A hair sample has the advantage that information is obtained on doping 
steroids accumulated in the past. Though a fingernail sample has a similar advantage, the 
number of papers concerning the use of human fingernail clippings is extremely low. For 
example, Choi and co-workers analysed testosterone and pregnenolone in nail[132]. 
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3.1.8. Difficulties in the analysis of doping steroids in nail 
The problems are basically brought together by the following two points. Firstly, 
the fingernail is composed of hard keratin. Therefore, it is difficult to extract doping 
steroids directly without degradation. Choi used alkaline digestion method for the 
analysis of testosterone and pregnenolone in nail [132]. However, if an alkaline digestion 
method were to be used for testosterone esters, the steroid esters could not be detected and 
quantified because of the decomposition of the esters by hydrolysis. 
The second reason is that, even if doping steroids are extracted from the fingernail, 
the amount of doping steroid in nail is extremely low just as are the endogenous sex 
hormones. Moreover, the extracts usually contain many interfering substances. 
3.1.9. Method of direct extraction of doping steroids from fingernail 
Cryogenic grinding was described in Chapter 2, using liquid nitrogen as a method 
of overcoming the difficulty of extracting drugs from fingernail clippings. 
Application of the cryogenic grinding method to analysis of cannabinoids [30] and 
opioids [133] in nail was extremely effective, and the analytes were extracted without 
degradation of morphine esters. A similar procedure was expected to be applicable for 
the analysis of steroid esters. 
3.1.10. Aims of this study 
The first objective was to apply the cryogenic grinding method to the extraction of 
doping steroids in the fingernail samples, and to verify the presence of steroids in nail. 
The second was to evaluate this alternative steroid extraction procedure for nail 
clippings from anabolic steroids abusers. 
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S4. ANABOLIC AGENTS 
1. Anabolic Androgenic Steroids (AASý 
a. Exogenous AAS including but not limited to: 
bolasterone, boldenone, boldione, clostebol, danazol, 
Itestosterone, &'-androstene-3,17-dione, drostanolone, 
fluoxymesterone, formebolone, gestrinone, 4-hydroxytestosterone, 
19-nortestosterone, mestanolone, mesterolone, methandienone, 
methandriol, methyltestosterone, mibolerone, nandrolone, 
9-norandrostenediol, 19-norandrostenedione, norbolethone, norethandrolone, 
oxandrolone, oxymesterone, oxymetholone, quinbolone, stanozolol, 
1-testosterone (0'-dihydrotestosterone), trenbolone and their analogues. 
h. Endogenous AAS including but not limited to: 
androstenedione, dehydroepiandrosterone (DHEA), 
testosterone and their analogues. 
* Note: Extracts from the WADA prohibited list, 2004 
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Table 3.2. USADA guide list (EXAMPLES OF ANABOLIC AGENTS) 
No. Generic Name Pharmaceutical Preparations Examples 
1 Androstenediol Androstederm, 4-Androstenediol, 
5-Androstenediol 
2 Androstenedione Andro Stack850, Andro-Gen, Androsten, 
Androstene 100, Testro Rx 
3 Bolasterone Dimethyltestosterone, Ma en 
4 Boldenone Equipoise, Vebonol 
5 Clostebol Steranabol 
6 Danazol Cyclomen, Danatrol, Danocrine, Danokrin, 
Danol, Ladogar, Win 17757, Winobanin 
7 Deh dro-Cl-Me-testosterone Turinabol 
8 Deh droe iandrosterone DHEA 
9 Dihydrotestosterone Stanolone 
10 Dimethyltestosterone Ma en 
11 Dromostanolone Drolban, Masteril 
12 Fluoxymesterone Android F, Halotestin, Ora-Testryl, Ultradren 
13 Formebolone Esiclene, Hubernol 
14 Gestrinone Tridomose 
15 Mesterolone Androviron, Proviron 
16 Metandienone Danabol, Dianabol 
17 Metenolone Primoboran, Primonabol-Depot 
18 Methandriol Stenediol, Trofomone 
19 Methyltestosterone Android, Estratest, Metandren, Oreton 
Methyl, Testred 
20 Mibolerone Cheque Drops 
21 Nandrolone Deca-Durabolin, Durabolin, Kabolin, 
Nandrobolic 
22 19-Norandrostenediol 19-Nor Diol, 19-Norandrobol, Norandrodiol, 
Norandronate 
23 19-Norandrostenedione 
19-Nor Androstene, 19-Nora Force, Anabolic 
Stack, Androbolic, Androdyne, Androstat 
Po ers, Androstat Pro 6, Ultimate Release 24 
24 Norbolethone 
25 Norethandrolone Nilevar 
26 Oxandrolone Anavar 
27 Oxymesterone Oranabol 10 
28 Oxymetholone Adroyd, Anadrol, Anapolon 
29 Stanozolol Stromba, Winstrol 
30 Testosterone T: E >6: 1 Delates 1, Malo en, Malo ex 
31 Trenbolone Finaiet, Parabolan 
`Notes: extracts from the TISADA guid e 
Beta-2 agonists are included in the class of anabolic agents. 
Authorised in the aerosol or inhalant forms only to prevent and/or treat asthma and 
exercise-induced asthma (EIA and EIB). 
According to the USADA guide, methandrostenolone (Dianabol) is repeated. 
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New controls on the supply of anabolic steroids 
Home Office 082/96,21 march 1996 ! 
ANABOLIC AND ANDROGENIC STEROIDS 
Atamestane Bolandiol Bolasterone Bolazine Boldenone Bolenol Bolmantalate 
Calusterone 4-Chloromethandienone Clostebol Drostanolone Enestebol Epitiostanol 
Ethyloestrenol Fluoxymesterone Formebolone Furazabol Mebolazine Mepitiostane 
Mesabolone Mestanolone Mesterolone Methandienone Methandriol Methenolone 
Methyltestosterone Metribolone Mibolerone Nandrolone Norboletone Norclostebol 
Norethandrolone Ovandrotone Oxabolone Oxandrolone Oxymesterone Oxymetholone 
Prasterone Propetandrol Quinbolone Roxibolone Silandrone Stanolone Stanozolol 
Stenbolone Testosterone Thiomesterone Trenbolone 
Polypeptide Hormones Chorionic Gonadotrophin (HCG) Non-human chorionic 
gonadotrophin Somatrotopin Somatrem Somatropin 
Andrenoceptor stimulant Clenbuterol 
*Note: Extracted from documents 
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3.2. Materials and Methods 
3.2.1. Nail samples 
Nail clippings from anabolic steroid users were obtained from the Institute of 
Doping Analysis/Sports Biochemistry, Kreischa. Blank nail samples were obtained 
from volunteers. 
3.2.2. Blood and urine samples 
Blood and urine samples were collected from volunteers for validation of the 
steroid analytical methods and to compare with the steroid concentrations in the nail 
samples. 
3.2.3. Reagents 
3.2.3.1. Standard steroid samples 
Standards were obtained from the following suppliers: 
Steraloids (RI, USA); 
Testosterone acetate, testosterone undecanoate, and testosterone benzoate. 
Testosterone homologues that are banned by the World Anti-Doping Agency 
(WADA) [Table 3.4], bolandiol, bolasterone, calusterone, canrenone, clostebol, 
dromostanolone, 11-ketotestosterone, mibolerone, and norgestrel. 
Sigma-Aldrich (Dorset, U. K. ); 
Androsterone (AND), dehydroepiandrosterone (DHEA), epiandrosterone 
(epiAND), and epitestosterone (epiTEST). 
Stanozolol (STN), fluoxymesterone, oxandrolone, 4-androstene-3,17-dione, 19- 
nor-4-androstene-3,17-dione, 19-nor-testosterone-17-decanoate (nandrolone decanoate), 
testosterone-17ß-esters, propionate, isocaproate, heptanoate (enanthate), decanoate, 
cypionate, and phenylpropionate 
IKAPHARM (Ramat-Can, Israel); 
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Etiocholanolone (ETIO). 
Cerilliant (Texas, USA); 
Oxymesterone, methenolone, Anabolic metabolites, 16ß-hydroxystanozolol, 3'- 
hydroxystanozolol, 6ß-hydroxyfluoxymesterone, 6ß, 11 ß-dihydroxyfluoxymesterone, 
6ß-hydroxy-methandienone, 5a-estran-3a-ol-17-one (Norandrosterone), and 5ß-estran- 
3a-ol-17-one (Noretiocholanolone). 
Research Biochemicals International (MA, USA) ; 
Testosterone propionate. 
Table 3.4. Chemical structures of typical exogenous anabolic steroids homologues 
* prohibited list from the WADA 
OH 
/? Is 
CH3 OH 
R» 
j H3 
C0 C-3 17 
1! 
ý, 13 
Di6 H 
R1ý 
-9 
H 
-14 
J9 
P 
3 
2! H8 !s 
c 
HH H 
s7 H 
6 
Testosterone (numbering) Estrogens Progestagens 
Testosterone homologues 
Subst. Subst. at 
Steroid Substituent groups at Cn position 
at C4 C17a 
Testosterone 17B-hydroxyandrost4-en-3 -one 
Bolasterone CH3 7a-Me- 
Boldenone 1,2-dehydro- 
Calusterone CH3 7a-Me- 
Clostebol Cl 
Dehydro-Cl-Me-testosterone Cl CH3 1,2-dehydro- 
Dihydrotestosterone 4,5-dihydro- 
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Dromostanolone 2a-Me-, 4,5-dihydro- 
Fluoxymesterone CH3 9-F-, 11 ß-OH- 
Formebolone CH3 1,2-dehydro-, 2-formyl-, lla- 
OH- 
Gestrinone CH=-C 9,10,11,12-dehydro-, 18a-Et-, 
19-nor- 
Mestanolone CH3 4,5-dihydro- 
Mesterolone la-Me-, 4,5-dihydro- 
Methandienone CH3 1,2-dehydro- 
Methenolone 1-Me-, 1,2-dehydro-, 4,5- 
dih dro- 
Methyltestosterone CH3 
Mibolerone CH3 7a-Me- 
Nandrolone 19-nor- 
Norbolethone CZHS 13ß-Et-, 19-nor- 
Norethandrolone CZHS 
Oxabolone OH 19-nor- 
Oxymesterone OH CH3 
Oxymetholone CH3 2-CH2OH- 
Quinbolone 1,2-deH-, 17ß-(1-cyclopenten-l- 
lox 
Stenbolone 2-Me-, 1,2-dehydro-, 4,5- 
dih dro- 
Trenbolone 9,10,11,12-dehydro-, 19-nor- 
Danazol* CH=C (2,3-d)isoxazol- 
Oxandrolone* CH3 2-oxa-, 4,5-dihydro- 
Stanozolol* CH3 2-eno(3,2-c)pyrazol-, 4,5- 
dih dro- 
* Heterocyclic anabolic steroid attached on the A ring. 
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3.2.3.2. Steroids for use as internal standards 
Deuterated testosterone (17ß-hydroxyandrost-4-en-3-one-16,16,17-d3, TEST-d3) 
was from Sigma-Aldrich. 
Deuterated 5a-estran-3ß-ol-17-one (19-nor-5a-androstan-3ß-of-17-one-3a, 4,5a-d3, 
norepiandrosterone-d3, NEA-d3) and stanozolol (17ß-hydroxy-17a-methylandrostano 
[3,2-c]pyrazole-20,20,20-d3, STN-d3) were from Cerilliant (Texas, USA). 
Medroxyprogesterone (17a-hydroxy-6a-methylpregn-4-ene-3,20-dione, MEDR) 
was from Steraloids. 
3.2.3.3. Other anabolic steroid alkanoic acid esters 
These steroids were synthesised by reaction of anabolic steroids with the 
corresponding alkanoic acid anhydrides or acyl chlorides using pyridine or 4,4'-bipyridyl 
as catalysts. 
These steroid acyl derivatives are shown in Tables 3.5-3.7 and Appendix (Table 
3.8) in bold and with double underscore. 
3.2.3.4. Hydrocarbon reagents for Kovat index (Retention index) 
Docosane (C22H46), octacosane (C28H58), triacosane (C30H62), dotriacosane (C32H66), 
tetratriacosane (C34H70), hexatriacosane (C36H74), octatriacosane (C38H78), and tetratetra- 
contane (C44H90) were purchased from Sigma-Aldrich. 
Tetracosane (C24H50) was from Ralph N Emanuel (Wembley, England). 
Hexacosane (C26H54), tetracontane (C40H82), and dotetracontane (C42H86) were from 
Fluka Chemie (Buchs, Switzerland). These hydrocarbons were dissolved in toluene 
(about 10 ng/µL) and used for measuring retention indices of anabolic steroids. 
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3.2.3.5. Solvents and reagents 
Methanol and ethyl acetate used were both high performance liquid 
chromatography (HPLC) grades from BDH Laboratory Supplies, U. K. 
N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA), 2-mercaptoethanol, and 
ammonium iodide were from Sigma-Aldrich. 
Other solvents and reagents used were all analytical reagent or HPLC grade. 
3.2.3.6. Solid phase extraction cartridges 
Solid phase extraction (SPE) cartridges were Worldwide Monitoring Clean 
Screen cartridges, CSDAU (200 mg, 10 mL, United Chemical Technologies Inc., 
Bristol, U. K. ), Varian Bond Elut LRC C18 cartridges, (200 mg, 10 mL, Varian, CA, 
USA), or Isolute-XL (200 mg, 10 mL, International Sorbent Technology Limited, 
MidGlamorgan, U. K. ). 
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3.2.4. Sample preparation 
3.2.4.1. Nail samples 
a) Decontamination of nail clippings 
The nail clippings were washed with 5 mL of 0.1 % sodium dodecyl sulfate (SDS) 
for 15 min using ultra-sonication. The samples were similarly washed three times with 5 
mL of de-ionised water and 5 mL of methanol, respectively. These methanolic washes 
were preserved for later reference. 
The washed nail clippings were' dried at room temperature. Each sample was 
weighed accurately. 
b) Extraction with cryogenic grinding method 
The washed nail clippings (1.84-75.28 mg) were pulverised with a cryogenic 
grinder (SPEX CertiPrep 6750 Freezer Mill) under freezing conditions with liquid 
nitrogen (LN). 
The powdered samples were extracted with 7 mL of methanol/ethyl acetate (7: 3, 
v/v) solution. Each of the internal standard solutions (10 µL of 1.00 ng/µL solutions of 
deuterated steroids NEA-d3 and TEST d3 and MEDR, respectively) was added to the 
solvent extracts and sonicated for 15 min. 
The extracts were vortex mixed for 30 sec and then centrifuged for 10 min at 2,000 
rpm. The supernatant was collected and evaporated to dryness at 60 °C under a stream of 
nitrogen. 
80 µL of 0.1 % ammonium iodide/methanol (w/v) solution was added to the residue 
as catalyst prior to trimethylsilyl derivatisation. The methanolic solvent was dried again 
under a stream of nitrogen. 
c) Trimethylsilyl derivatisation for gas chromatography-mass spectrometric analyses 
The residues were derivatised with 40 µL of MSTFA with 2-mercaptoethanol 
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(1,000: 6, v/v) for 15 min at 60 °C. Derivatised samples were transferred to autosampler 
vials of the GC-MS instrument. 
d) Gas chromatography-mass spectrometric (GC-MS) analysis 
Qualitative and quantitative analysis were carried out with a Finnigan Trace GC- 
MS instrument equipped with an AS 2000 autosampler. Data was acquired using the 
Xcalibur software from Finnigan in full scan and selected ion monitoring (SIM) modes. 
A 3-4 µL aliquot of derivatised analytes were analysed on an HP-5 column (30 mx 
0.32 mm i. d.; film thickness 0.25 µm) with helium (0.9 mL/min) as carrier gas, 
temperature programming from 180 °C to 240 °C at 3 °C/min, 240 °C to 300 °C at 5 
°C/min (held for 10-15 min), and 70 eV electron energy in the SIM. 
Interface and ion source temperature, emission current, and detector voltage, were 
250 °C, 200 °C, 350 VA, and 750 V, respectively. Mass spectra and SIM data were 
acquired using the EI+ mode at 70 eV electron energy. 
An alternative temperature programme was used to analyse all steroids such as 
anabolic, estrogens, progestagens steroids, and so on. The temperature programme was 
150 °C to 250 °C at 10 °C/min, 250 °C to 300 °C at 5 °C/min (held for 7 min). 
3.2.4.2 Blood (plasma) samples 
a) Blood samples 
The samples were centrifuged for 10 min at 2,000 rpm and the supernatant (plasma) 
was collected. The plasma was stored in refrigerator at 4 °C until analysed. 
b) SPE of plasma 
Solid phase extraction (SPE) was carried out using the IST Vac/Master vacuum 
work station from International Sorbent Technology, U. K. 
One (1) mL of each plasma sample was loaded after the SPE cartridges (Bond Elut 
76 
C18) had been conditioned with 2 mL of methanol, and 2 mL of de-ionised water, 
respectively. 
The cartridges were washed with 1.0 mL of de-ionised water. Subsequently, the 
cartridges were dried under vacuum for 10 min using a Millipore (MA, USA) diaphragm 
vacuum pump. 
Analytes were eluted with 2 mL of methanol. The eluates were collected and the 
extracts were evaporated to dryness under a stream of nitrogen. 
80 µL of 0.1% ammonium iodide/methanol solution was added to the extracts as 
catalyst prior to trimethylsilyl derivatisation. The methanolic ammonium solutions were 
evaporated to dryness with nitrogen gas at 60 °C. The residues were dried under vacuum 
for 30 min. 
The analytical samples contain moisture when the samples are extracted by the SPE 
method and when the SPE method was used, vacuum drying was applied to dry the 
samples. 
c) Trimethylsilyl derivatisation for GC-MS analyses 
The residues were derivatised with 40 µL of MSTFA with 2-mercaptoethanol 
(1,000: 6, v/v) for 15 min at 60 T. Derivatised samples were then transferred to 
autosampler vials for GC-MS analysis. 
3.2.4.3. Urine samples 
Steroids were extracted from urine samples by SPE. The extracts were then 
subjected to enzymatic hydrolysis and re-extracted. Details are as follows. 
a) SPE extraction for conjugated and free steroids 
The urine samples were not centrifuged because there were no precipitates. 
Fifteen (15) µL of each internal standard solution (each containing 1 ng/µL of 
NEA-d3, TEST-d3, MEDR, apart from STN-d3, which contained 2 ng/µL) were added to 5 
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mL of urine sample, respectively. 
The samples were vortex-mixed for 30 sec and loaded on Varian Bond Elut LRC 
C, $ SPE cartridges (200 mg) which had been conditioned with 3 mL of methanol and 3 
mL of de-ionised water, respectively beforehand. 
The cartridges were then washed with 3 mL of de-ionised water and subsequently 
dried for 10 min under vacuum using a diaphragm vacuum pump. 
The analytes were eluted with 4 mL of methanol. The eluates were evaporated to 
dryness under a stream of nitrogen. 
b) Enzymatic hydrolysis of conjugated steroids 
The extraction residues were dissolved in 600 µL of 0.2 M potassium phosphate 
buffer at pH 6.8,400 µL of ß-glucuronidase (Escherichia coli, 400 Units) were added 
and the solutions were incubated at 60 °C for 3 h. 
c) SPE extraction of hydrolysates 
The deconjugated and free steroids were extracted by SPE as follows. 
The cartridges (Varian Bond Elut LRC C18 SPE cartridge, 200 mg) were activated 
with 2 mL of methanol and 2 mL of de-ionised water, respectively. The hydrolysed 
samples were loaded to the cartridges after the samples were vortex-mixed for 30 sec. 
Then, the cartridges were washed with 2 mL of de-ionised water. 
Subsequently, the cartridges were dried for 10 min under vacuum using a 
diaphragm vacuum pump. The analytes were eluted with 3 mL of methanol. 
The eluates were evaporated to dryness under a stream of nitrogen. One hundred 
and twenty (120) µL of 0.1% methanolic ammonium iodide solution was added to the 
residue as catalyst prior to trimethylsilyl derivatisation. The solution was dried under a 
stream of nitrogen. 
The residue was then completely dried again under vacuum using a diaphragm 
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vacuum pump. 
d) Trimethylsilyl derivatisation for GC-MS analyses 
The extraction residues were derivatised with 60 µL of MSTFA with 2-mercapto- 
ethanol (1,000: 6, v/v) as catalyst for 15 min at 60 T. 
Derivatised samples were transferred to autosampler vials for GC-MS analysis. 
3.2.5. Qualitative analysis of endogenous steroids 
To determine the retention time, relative retention time (RRT), retention index, and 
mass spectrum (MS) of each steroid under the GC-MS conditions described earlier, 
TEST and hydrocarbons were used as internal standard and retention index standards 
respectively. 
The sample concentration of each steroid was in the range I to 5 ng/µL of reagent 
containing hydrocarbon for measurement of Kovat indices (Retention Indices). 
3.2.6. Qualitative analysis of exogenous steroids 
To identify and determine exogenous (synthetic) steroids, NEA-d3, TEST-d3, 
MEDR, and STN-d3 were used for GC-MS analysis as internal standards. 
The temperature programmes used were: 
" 150 °C to 250 °C at 10 °C/min, 250 °C to 300 °C at 5 °C/min (held for 7 min), and 
9 180 °C to 240 °C at 3 °C/min, 240 °C to 300 °C at 5 °C/min (held for 10-15 min). 
3.2.7. Quantitative analysis of endogenous steroids 
3.2.7.1. Preparation of standard samples for calibration curves 
All standard steroids were prepared to give stock solutions with a concentration of 
1.0 mg/mL in methanol/ethyl acetate (70: 30, v/v). Working solutions containing 0.04 
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ng/µL were then prepared by diluting the stock solutions. 
The standard sample solutions prepared were separately collected in small vials 
containing each of the following volume: 0,5.0,12.50,25.0,125.0,250.0 and 500.0 µL 
using working solution (0.04 ng/µL), respectively. Internal standard solutions (10 µL of 
1 ng/µL of NEA-d3 and TEST-d3) were added to each of the vials at the same time. 
These samples were evaporated, derivatised, and prepared for the calibration curves 
by the same method as described earlier for the sample preparation of nail. 
3.2.7.2. Calibration curves for endogenous steroids in nail, plasma and urine samples 
The SIM mode was used for the quantitative analysis of each steroid. 
Four (4) µL of each standard solution containing 0.00,0.005,0.0125,0.0250,0.125, 
0.250 and 0.500 ng/pL were injected into the GC-MS respectively. The peak area ratios 
of the standards in each sample to an internal standard were used for the preparation of the 
calibration curves for quantitative analysis of endogenous steroids. 
3.2.7.3. Fragment ions used for SIM 
The quantified compounds and selected ions were as follows. NEA-d3 (m/z 423) 
was used for AND (m/z 434) and ETIO (Wz 434) as internal standard. Similarly, 
TEST-d3 (m/z 435) was used for the DHEA (m/z 432), epiAND (m/z 434), epiTEST (m/z 
432), and TEST (m/z 432) as internal standard 
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3.3. Results and Discussion 
3.3.1. Methanolic ethyl acetate extraction with the cryogenic grinding method 
A direct extraction method was developed for steroids in nail clippings which was 
almost the same as the method used previously for cannabinoids and opioids in nail [30]. 
However, the extraction solvent was different and the conditions with respect to the 
time used to cool the grinder with liquid nitrogen and interval times used to pulverise the 
frozen nail with the cryogenic grinder were examined and optimised. 
As a result, effective conditions were found to be a pre-cooling time of 2 min and a 
grinding time for 2 min, which was carried out twice in the cycle with a 1-min re-cooling 
period between each grinding period. 
The type of solvent used to extract the steroids from the pulverised nail was 
considered. The solvents tried were acetone, acetonitrile, chloroform, ethyl acetate, 
hexane, and methanol. As a result, a mixture of methanol/ethyl acetate (70: 30, v/v) was 
selected in consideration of the low background, the easiness of the solvent to handle, and 
solubilities of the analytes. 
Impurities (contaminants) detected in the methanol/ethyl acetate blank solution 
were mainly phthalic acid esters (dibutyl (DBP) and dioctyl (DOP)). These components 
originate chiefly in plastic additives derived from laboratory-wares. 
3.3.2. Derivatisation of analytes 
One of the most important factors in GC-MS analysis is what derivatisation to use 
to prepare the steroid extracts. 
Anabolic steroids can be analysed by GC-MS without derivatisation though the 
sample steroids have either hydroxyl or amino functional groups or both [Figure 3.1, 
Table 3.4]. 
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In GC-MS analysis of steroid samples, derivatisation is used to improve the 
analytical sensitivity and retention times, to increase the thermal and chemical stability of 
the analytes and their volatility, and to make identification of molecular ions easier (e. g. 
tertiary butyldimethylsilyl ether derivatives give prominent M-57 ions). In general, 
silylation, acylation and other methods have mostly been used for the derivatisation of 
steroids to improve the performance of the GC-MS analysis. 
The advantages of silyl derivatives are that they are easy to prepare and the 
derivatives are volatile compounds. On the other hand, the disadvantage of silyl 
derivatives is that they react with moisture (water) and other hydroxylic solvents such as 
methanol. 
While many different silyl ethers and esters have been used, trimethylsilyl (TMS) 
derivatives have been most widely accepted as the preferred silyl derivatives for steroids 
for GC-MS analysis. The literature concerning TMS derivatisation of anabolic steroids 
up to 1996 was reviewed in detail by Opfermann [134]. New derivatisation methods 
have been successively reported as the chemistry develops. 
Ayotte [135], Wolthers [136] and Segura [137] evaluated recent analytical 
methods for doping steroids in detail in their reviews. The merits and weak points of the 
steroid derivatives in GC-MS analysis are described in more detail below. 
3.3.2.1. Silyl derivatives 
There are several kinds of silylating method. In general, TMS derivatives of 
testosterone are roughly classified into three types. The first is testosterone-17-mono- 
TMS derivative in which only the hydroxy group at C17-position is derivatised as 
showing in Figure 3.5. 
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TMS 
H 
Figure 3.5. Chemical structure of Testosterone-17-mono-TMS 
The second type is testosterone-3-methyloxime-17-TMS derivative in which the 
ketone group at C3-position reacts with methoxyamine and TMS reagents consecutively 
as shown in Figure 3.6 [92,104,138,139,140,141]. 
One disadvantage of methyloxime derivatives of 3-keto-a-4-steroids is that two 
geometric isomers (syn and anti) are obtained which differ according to the orientation of 
the methoxy group. 
The two isomers do not interchange readily and as a result two peaks are usually 
obtained during GC analysis. Replacement of the methyl group of the oxime with a larger 
substituent, such as butyl or benzyl, results in a marked stereo-chemical preference for 
one of the two isomers and, subsequently, in a single GC peak. However, these heavier 
substituents also result in a correspondingly longer retention time, particularly if two 
ketone groups are initially present leading to a double oxime derivative. 
CH3o- 
Figure 3.6. Chemical structure of Testosterone-3-N-methyloxime-17-mono-TMS 
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The third testosterone TMS derivative is testosterone-3,17-di-TMS derivative in 
which both an enolic hydroxyl group at the C3-position and the hydroxy group at the 
C 17-position are derivatised as shown in Figure 3.7. 
Figure 3.7. Chemical structure of Testosterone-3,17-di-TMS 
In addition, there is another TMS derivative in which the ketone group at the C3- 
position is reacted with hydroxylamine and then with TMS reagent in succession, such 
that both the oxime and at C 17-hydroxyl groups are derivatised at the same time, as 
shown in Figure 3.8 but this type of derivative is very rarely used [142]. 
[BIS 
Ei 
TMS-0 N 
Figure 3.8. Chemical structure of Testosterone-3-oxime, 17-di-TMS 
To prepare testosterone-3,17-di-TMS derivative, the enolic hydroxyl group does 
not readily form and react in the presence of the TMS reagent alone and it is necessary to 
add a catalyst. Iodine compounds such as ammonium iodide and trimethylsilyl iodide are 
often used as the catalyst for derivatising testosterone and its analogues. However, a 
reducing agent is also needed together with TMS reagent. 
N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA, see Figure 3.9) has been 
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widely used as the TMS reagent for silylation of steroids together with a catalyst and 
reducing agent. A number of different reagents were evaluated for the present study and 
the combinations of TMS derivatising reagents are described in detail below. 
CF3C0 N`-Sl(CH3)3 
CH3 
Figure 3.9. Chemical structure of MSTFA 
1) TMS reagent #1: MSTFA/NH4U1,2-Ethanedithiol (1,000: 2: 6, v/w/v), 60 °C, 15 min 
Silylation using this combination of TMS reagents has been widely used [143,144, 
145,146,147,148,149,150,151,152,153,154]. However, 1,2-ethanedithiol (CZH6S2 = 
94.20) is difficult to use in practice because of its strong odour. 
As for the relative proportions of the MSTFA, NH4!, and 1,2-ethanedithiol reagents, 
the ratios of 1,000: 2: 6 (v/w/v) are generally used. Moreover, the temperature and the 
reaction time are commonly set at 60 °C for 15 min for sample derivatisation. 
2) TMS reagent #2: MSTFA/NH, I/2-Mercaptoethanol (1,000: 2: 6, v/w/v), 60 °C, 15 min 
It is easy in practice to handle 2-mercaptoethanol (CZH60S = 78.13) because, 
although it also has a strong smell, it is considerably less than that of 1,2-ethanedithiol. 
The conditions for sample derivatisation are also almost the same as the above-mentioned 
method [111,116,155]. 
In this thesis, the above method was used for trimethylsilylation of steroids. The 
advantage of this method is that MSTFA, as well as the by-products N-methyl- 
trifluoro-acetamide (C3H, F3NO = 127.07) and 2-mercaptoethanol-di-TMS 
(CgH220SSi2 = 222.50), are very volatile liquids and do not interfere in the GC-MS 
analysis. The silylation reaction mixture can be injected directly into the GC and there is 
no need to use solvent for reconstituting the derivatised analytes for GC-MS analysis. 
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However, when this method was applied to steroids having an enolic hydroxy group, 
the TMS derivative was sometimes not obtained. One reason is that because ammonium 
iodide is a solid, it is not easy to dissolve it in MSTFA. An additional reason is that it was 
difficult to prepare a reagent with an exact ratio of TMS reagent to ammonium iodide of 
1,000: 2. Therefore, a 0.1% methanolic ammonium iodide solution was prepared and this 
solution plus twice the amount of MSTFA reagent was added to the steroid samples. As a 
result, it was ascertained that the steroids were completely derivatised. 
The greatest advantage of MSTFA reagent is that it can easily derivatise functional 
groups such as the enolic ketone group at the C3-position as well as the sterically 
hindered hydroxy group at 17a-position of steroids. 
When hydrocortisone (pregn-4-ene-11ß, 17a, 21-triol-3,20-dione, C21H3005 = 
362.47) was tried as an example, all functional groups of the hydrocortisone were 
completely converted to TMS derivatives (MW = 722) [Figure 3.10]. 
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The enolic ketone (C3), sterically hindered hydroxy (C17), and ketol (C20) groups 
were completely derivatised. 
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Therefore, when the TMS derivative is prepared with MSTFA reagent, the selection 
of the reducing agent and the catalyst is just as important as the choice of the silylating 
reagent itself. 
3) TMS reagent #3: MSTFA/NH4I/Propanedithiol (1,000: 2: 3, v/w/v), 60 °C, 60 min 
A method using propanedithiol (C3H8S2 = 108.23) as a replacement for 1,2- 
ethanedithiol has been reported [156]. 
4) TMS reagent #4: MSTFA/NH4U1,4-Dithioerythritol (1,000: 2: 4, v/w/w), 60 °C, 15 min 
This TMS reagent has been widely used [141,157,158,159,160,161,162,163, 
164,165]. The 1,4-dithio-erythritol (DTE, C4H1002S2 = 154.26) reagent is a solid, and 
this catalyst has been used as a replacement for the above-mentioned alkyl thiol reducing 
agents. There is no offensive smell, and it is easy to handle, though it is expensive. 
However, it is difficult to prepare the silanising reagent mixture containing DTE in 
exactly the specified ratio, as previously described. This problem is described in detail 
below. 
5) TMS reagent 405: MSTFA/TMSI/DTE (1,000: 5: 5; v/v/w), 60 °C, 40 min 
This TMS reagent uses trimethylsilyl iodide (TMSI, C3H9ISi = 200.10) as a 
replacement for ammonium iodide as catalyst [97,104,166,1671. 
As for the ratios of the reagents MSTFA, TMSI, and DTE in the mixture, 1,000: 5: 5 
is used. For the conditions of the derivatisation reaction, the temperature is 60 °C but the 
time required is a little long reaction. 
With respect to the weight of DTE used, DTE is a solid and present in trace amounts 
compared to MSTFA. Therefore, there are some reports in the literature in which the 
87 
ratios of the TMS reagents are vaguely expressed, for example: 
(1) a spatula tip of the reductant DTE in MSTFA [168] 
(2) approximately 2 mg [169] 
(3) MSTFA/TMSI/DTE (1,000/2/1 mg) [170] 
It is usually difficult to weigh a trace amount (1 mg) of DTE accurately compared 
with the large amount of MSTFA (1,000 µL). Many authors prepared a large volume of 
reagent and stored it in the refrigerator until used. 
6) TMS reagent #06: MSTFA/Trimethylsilyl iodide (TMSI)/DTE or Ethanedithiol 
In this reagent, TMSI is used as a replacement for ammonium iodide as a catalyst. 
DTE [162] or ethanedithiol [135] is used as a reducing agent. 
7) TMS reagent #07: MSTFA/Imidazole (1,000: 2, v/w), 60 °C, 15 min 
According to the Schanzer's report, this TMS reagent is equivalent to a mixture of 
MSTFA/NH4Uethanedithiol (1,000: 2: 6, v/w/v) reagent [144,145,171]. 
8) TMS reagent #08: Hydroxylamine/Pyridine (0.3%), 60 °C, 60 min, followed by 
MSTFA/TMSI/DTE (1,000: 5: 5; v/v/w), 80 °C, 60 min 
As shown in Figures 3.6 and 3.8, the ketone group at the C3-position of the steroid 
was derivatised with TMS reagent after derivatisation with hydroxylamine (HONH2 = 
33.03) or methoxyamine (CH3ONH2 = 47.06) [92,104,13 8,13 9,140,14 1 ]. There is one 
report in which ethoxyamine (C2HSONH2 = 61.09) has been used as a replacement for 
methoxyamine [140]. 
3.3.2.2. Acyl derivatives 
Acyl derivatives as well as TMS derivatives have been commonly used for GC-MS 
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analysis. In particular, heptafluorobutyric derivatives prepared with heptafluorobutyric 
anhydride (HFBA, C8F1403 = 410.10) have been reported. 
As the molecular weight of the derivative increases, the sensitivity of detection 
rises and the acylation of steroids progresses as well as the trimethylsilylation reaction. 
However, to get high sensitivity in the detection of mass fragment ions in the high 
mass range, more than m/z 600, in a conventional bench top GC-MS instrument can be 
difficult. 
1) Acylation reagent #O1: Heptafluorobutyric anhydride (HFBA) [158,172,173] 
Williams [95] used this heptafluorobutyryl (HFB) derivative to analyse anabolic 
steroids in the racing greyhound. Moreov er, Ferchaud [97] reported on the HFB 
derivative to improve the sensitivity of GC-MS analysis of stanozolol in domestic 
animals. 
Both alcoholic hydroxyl and amino groups of anabolic steroids react with HFBA 
reagent. HFB derivatives are stable compounds as they are either ester (-O-COC3F7) or 
the acid amide (N-COC3F7). The sensitivity of GC-MS analysis increases at the same 
time, too. The sensitivity is especially remarkable in the negative ion chemical ionisation 
-mass spectrometry (NCI-MS) mode. 
2) Acylation reagent #02: Acetic anhydride 
Acetic anhydride (C4H603 =102.10) has generally been used for isotope ratio GC- 
MS of anabolic steroids [174,175,176,177]. Anabolic acetate derivatives are shown in 
the Appendix (Table 3.8). 
3) Acylation reagent #03: Trifluoroacetic anhydride 
This esterification method uses trifluoroacetic anhydride (TFAA, C4F603 = 210.04) 
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reagent, giving a derivative with high cost-effectiveness which is obtained with a 
comparatively easy experimental procedure. Choi [174] applied the TFAA reagent to 
the analysis of anabolic steroids in equine plasma and urine. 
4) Other reagents #01: Heptafluorobutyryl/Pentafluorobenzyloxime 
Hold [114] and De Boer [175] used HFBA and O-(pentafluorobenzyl)hydroxy- 
amine (PFBO, C7H4FSNO = 213.12) for derivatisation of anabolic steroids in the hair and 
urine of pregnant women. 
HFBA and the PFBO reagents react with hydroxy group at the C17-position and 
enolised ketone at the C3-position of steroids, respectively [Figure 3.11]. 
C6F -CH 
Figure 3.11. Chemical structure of HFB-PFBO ester/oxime derivative of Testosterone 
5) Other reagents #02: Pentafluorophenyldimethylsilyl (Flophemesyl) ether - TMS enol 
ether (MSTFA/NH4I/DTE) (1,000: 4: 5, v/w/w), 60 °C, 15 min, 
This TMS reagent was used for the analysis of testosterone and pregnenolone in 
nail by Choi [132]. The alcoholic hydroxy group at the C17-position of anabolic steroids 
was derivatised with flophemesyl chloride (C8H6CJF5Si = 260.67), following which an 
enolic hydroxy group at the C3-position was derivatised with the TMS reagent (Figure 
3.12). 
90 
CH3 
CHj a si-c6F5 
lI HH3 
CH3 IH 
HIH 
/ \\ 
Figure 3.12. Chemical structure of Testosterone Flophemesyl-TMS ether derivative 
This derivative, as well as Hold's method, gives good sensitivity, but the fragment 
ions of the analytes are in the high mass range. Therefore, a high resolution mass 
spectrometer is needed, although a bench-top quadrupole mass spectrometer was used. 
6) Other reagents #03: N-methyl-N-trimethylsilyl-heptafluorobutyramide (MSHFB)/ 
trimethylchlorosilane/trimethylsilylimidazole (TMSimidazole) (100: 5: 2, v/v/v). 
Kim [180] has reported this TMS reagent for the analysis of furazabol and its 
metabolites. This method is the same as the conventional TMS derivatisation methods 
and has no significant unusual features. 
3.3.2.3. Formation of cyclic derivatives 
Examples of these include methyl, butyl or phenylboronate derivatives. These 
derivatives containing boron are prepared by reaction of dihydroxy steroids that are 
metabolites of the anabolic steroids with alkyl boronic acids. 
Methylboronic acid and butylboronic acid [ 140] or phenylboronic acid [ 176] were 
reported as derivatising reagents for stanozolol and fluoxymesterone, respectively. 
3.3.2.4. Miscellaneous derivatives 
One example is MSTFA/I2. In general, GC-MS analyses of anabolic steroids 
containing a hetero-atom ring in the steroid skeleton (stanozolol, danazol) and anabolic 
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steroids having multiple double bonds in the steroid nucleus (e. g. trenbolone) are difficult 
because of thermal degradation and HPLC based methods have been used in preference. 
This problem in GC-MS analysis of thermally labile compounds was improved by the 
derivative shown in Figure 3.13 [167,177]. 
rMs 
TMS- 
N-CH3 
COCF3 
Figure 3.13. Chemical structure of Trenbolone-4-(N-methyl, N-trifluoroacetyl)-3,17-di- 
TMS 
3.3.3. Qualitative and quantitative GC-MS analyses 
3.3.3.1. Qualitative analysis 
a) Gas chromatographic retention times and retention indices. 
More than 600 anabolic steroid compounds and their metabolites, estrogens, 
progestagens and glucocorticosteroids were identified from the literature [Appendix 
(Table 3.8)], and, of these, 125 steroids were obtained for this project and analysed by 
GC-MS. 
All of these steroid compounds eluted within the range of 10-25 min as shown in 
Tables 3.5-3.7. Relative retention times (RRT) were measured relative to the retention 
time of testosterone. Retention indices (Kovats indices) were also measured at the same 
time using n-hydrocarbon standards. 
In general, long retention times were obtained for anabolic steroids having an alkyl 
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ester group at the C 17-position. As examples, testosterone esters eluted in order of the 
carbon number of the alkyl substituent group, as shown in Table 3.5 (page 67). Similarly, 
GC-MS analysis data for other anabolic steroids and for other types of steroid 
(metabolites, estrogens, progestagens, etc) are shown in Tables 3.6 and 3.7 (pp 68-73), 
respectively. 
Dioctyl phthalate (di-ethylhexyl phthalate, DOP, C24H34024 = 390.56) and 
cholesterol (delta-5-cholesterol, C27H460 = 386.67) appeared as large, broad peaks. 
The DOP was a contaminant compound derived from plastics as previously 
mentioned. To prevent or reduce interference by DOP, plastic screw caps used for 
sample preparation tubes were washed with methanol beforehand. 
As a result, the peak intensity of DOP was decreased, but nevertheless was still large. 
Cholesterol was mainly derived from biological samples such as urine and plasma 
samples. Both DOP and cholesterol were interfering compounds though they played a 
role as markers of retention times (Rt). 
b) Mass spectra 
TMS derivatives of exogenous (synthetic) anabolic steroids controlled by WADA 
gave mass spectra that showed that all functional groups that could be silylated were 
completely derivatised with TMS reagent, except for oxandrolone. For example, danazol 
has one active hydrogen group (proton) on the 17ß hydroxy group and the number of 
TMS substituent groups in the TMS derivative of danazol is naturally one [Figure 3.14]. 
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=CH 
Figure 3.14. Chemical structure of Danazol-mono-TMS derivative 
The TMS derivative of oxandrolone gave a mass spectrum corresponding to a 
mono-TMS derivative (MW = 378) whereas Heunerbein [146] had reported that the 
oxandrolone TMS derivative has two TMS substituent groups. However, this report is 
incorrect because the ketone group at the C3-position of oxandrolone forms a lactone ring 
with the steroid skeleton [Figure 3.15] and the ketone group of a lactone is not amenable 
to enolisation. 
Therefore, the enol group cannot be formed, and the ketone group of the 
oxandrolone cannot be derivatised with TMS reagent. 
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Figure 3.15. Mass spectrum of Oxandrolone-mono-TMS 
The molecular ion and M-15 ion appear at m/z 378 and m/z 363 respectively. 
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The mass spectra of TMS derivatives usually gave the M-15 ion along with the 
molecular ion (M+), and the identification of the TMS derivative was easy by comparing 
it with a standard, excluding isomers, which tend to have similar spectra. The mass 
spectrum of the TMS derivative of testosterone is shown in Figure 3.20. 
c) Steroids that are difficult to analyse by GC-MS 
In the GC-MS analysis of stanozolol or danazol, an acceptable chromatogram was 
obtained only when a new septum and liner were used in the injection port of the GC. 
The chromatograms were not reproducible. In particular, stanozolol did not give 
good results because of pyrolysis, which occurred under the usual GC-MS conditions. 
Many workers have reported methods to improve the GC-MS analysis of stanozolol 
[97,107,130,131,144,146,178,179,180,181,182]. 
A similar result was obtained with trenbolone. However, judging from the results 
of GC-MS analysis, the data showed that the derivative had two hydroxy groups at the 
C II and C 12-positions of the anabolic steroid skeleton, probably resulting from an 
intermediate epoxide. Therefore, it seemed likely that trenbolone, which had been stored 
for a long time, had been oxidised (degraded) [see Figure 3.16]. 
q q 
Trenbolone Trenbolone -11,12-epoxide 11,1 2-Dihydroxytrenbolone 
Figure 3.16. Proposed oxidation of Trenbolone 
3.3.3.2. Identification of endogenous anabolic steroids in nail samples. 
Identification of endogenous steroids was carried out based on the data in Tables 
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3.5-3.7 and Table 8 in Appendix. As a result, the retention times of the endogenous 
anabolic steroids were chiefly between internal standard steroid, nor-epiandrosterone-d3 
(15.84 min) and testosterone-d3 (19.54 min) [Figure 3.17]. 
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Figure 3.17. Mass chromatograms (MC) of nail (Sample No. 190404sim03) 
Androsterone (16.06 min), etiocholanolone, dehydroepiandrosterone (17.89 min), 
epiandrosterone (18.04 min), epitestosterone (18.52 min) and testosterone (19.59 min) 
were detected in nail samples using retention times, mass chromatograms (MC), and 
standard samples [Figure 3.18-3.19]. 
The retention times of endogenous steroid standards and DOP were: NEA-d3 (15.90 
min), AND (16.11 min), ETIO (16.27 min), DOP (16.38 min), epiAND (18.10 min), 
epiTEST (18.58 min), TEST-d3(19.60 min), and TEST (19.64 min) [Figure 3.18]. Note 
that the dates of Figures 3.17 and 3.18 are different. Mass chromatograms of standard 
endogenous steroids, recorded on a different date of analysis, are shown in Figure 3.18. 
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Figure 3.18. Mass chromatograms of 3.75 ng of standard endogenous steroids (Sample 
No. 170304simIS) 
The retention times of endogenous standard steroids and DOP in Figure 3.17 were: 
NEA-d3 (15.90 min), androsterone (16.11 min), etiocholanolone (16.27 min), DOP (16.38 
min), epiandrosterone (18.10 min), epitestosterone (18.58 min), testosterone-d3 (19.60 
min), and testosterone (19.64 min). 
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Figure 3.19. MC of 0.10 ng of standard endogenous steroids (Sample No. 220504sim44) 
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The retention times of the endogenous standard steroids and DOP in Figure 3.19 
were: NEA-d3 (13.58 min), androsterone (13.81 min), etiocholanolone (13.98 min), DOP 
(14.10 min), DHEA (15.53 min), epiandrosterone (15.66 min), epitestosterone (16.13 
min), testosterone-d3 (17.07 min) and testosterone (17.12 min). 
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Figure 3.20. Mass spectrum of Testosterone-di-TMS 
The molecular ion and M-15 ion appear strongly at (m/z 432) and (m/z 417) respectively. 
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3.3.3.3. Identification of exogenous anabolic steroids in nail samples 
Concerning the nail samples from the steroid abusers, the concentrations of each 
steroid in hair and urine are shown in Table 3.9. All exogenous anabolic steroids present 
in the hair and urine samples were screened in the hair samples. Mass fragment ions 
(MF) used are shown in Table 3.9. The Retention index (R. I) of the steroids, measured 
with an initial programme temperature of 150 °C, are also shown in the Tables 3.5-3.7. 
TEST d3, MEDR, and STN-d3 were used as internal standards for the analysis of 
exogenous steroids that eluted after testosterone. STN-d3 was not suitable because of 
thermal degradation. Therefore, MEDR was used as the internal standard. Moreover, 
cholesterol, which was a major contaminant in steroid extracts of biological samples, was 
used as an additional marker of retention times. The exogenous steroids expected to be 
present on the basis of the urine and hair analysis could not all be detected because of 
interfering compounds and only testosterone isocaproate [Figures 3.21 and 3.22] and 
testosterone enanthate [Figures 3.28 and 3.29] were tentatively identified. 
(1) Testosterone isocaproate. 
In the mass chromatogram (MC) of Figures 3.21 and 3.22, the internal standard 
peak for medroxyprogesterone (m/z 560) appears at 26.55 min. Retention times of steroid 
TMS derivatives were: cholesterol (27.78 min), 4-cholesten-3ß-ol (27.83 min), other 
isomers of cholesterol (27.92 min), testosterone isocaproate (28.16 min), 7-cholesten- 
3ß-ol (28.64 min), respectively. The mass spectrum and retention time of the peak at 
28.16 min in the Figures 3.21 and 3.22 are in agreement with those of standard 
testosterone isocaproate (T-isocaproate) (see Figure 3.26). However, the presence of 
T-isocaproate remains tentative because of interference in the mass spectra, even though 
the retention time in the gas chromatogram matched that of the standard. 
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Table 3.9. Nail samples from suspected steroid abusers 
No. Compound Urine 
Hair 
(pg/mg) RRT RI 
MF 
(m/z) 
Nail 
Wt (mg) 
BI Clenbuterol + 250 ----- 2164 86,262 
Testosterone (T/E) 53 1.000 2707 432 
Testosterone enanthate 145 1.541 3329 472 
Methenolone + 1.026 2737 446, (194) 8 32 
Methenolone acetate 385 1.106 2831 416, (194) . 
Stanozolol + n. a 1.408 3165 472 
Oxandrolone + n. a 1.154 2897 143,378 
Fluoxymesterone + n. a 1.224 2976 552, (143) 
B2 Testosterone T/E 36 1.000 2707 432 
Testosterone enanthate 23 1.541 3329 472 
Nandrolone + 0.966 2661 418, (194) 
Nandrolone decanoate 810 1.824 3613 500 15.10 
Methandienone + 86 1.063 2781444 
Mesterolone + 10 0.987 2687 448 
Tamoxifen + n. a -- -- 371,72 
B3 Clenbuterol negative 35 -- 2164 86,262 
Testosterone T/E) 292 1.000 2707 432 
Testosterone enanthate 20 1.541 3329 472 1 84 
Testosterone decanoate 18 1.878 3648 514 . 
Stanozolol + 1.408 3165 472 
B4 Testosterone T/E 30 1.000 2707 432 
Testosterone enanthate 25 1.541 3329 472 
Testosterone phenylpropionate 425 1.930 3687 492 
Testosterone decanoate 220 1.878 3648 514 
Testosterone isocaproate 340 1.401 2975 458 
Methenolone + 1.026 2737 446 4.24 
Methenolone acetate 155 1.106 2831 416 
Methandienone + 97 1.063 2781 444 
Stanozolol + n. a 1.408 3165 472 
Furosemide + n. a - 81 
B5 Norandrost-4-ene-3ß, 17ß-diol ???? ? 2590 420 91 35 
Norandrost-4-ene-3,17-dione 0.950 2644 416 . 
Internal standard (I. Std) 
C 5a-Estran-3ß-o1-17-one-D3 0.876 2541 423 
Testosterone-D3 0.998 2704 435 
Medrox ro esterone 1.304 3070 560 
Stanozolol-D3 1.392 3163 475 
Notes: Analytical data for urine (ratio of testosterone/epitestosterone), RRT = Relative 
retention time (Testosterone = 1.000), R. I = Retention index, MF = mass fragment ions 
for quantitation (m/z), Wt = weight (mg) of decontaminated nail. 
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Figure 3.21. Mass chromatogram of nail #04 from anabolic steroid abuser (for 
Testosterone- l7-isocaproate-mono-TMS) 
The peak at retention time 28.16 min is tentatively identified as Testosterone-isocaproate. 
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Figure 3.22. MC of nail #04 from anabolic steroid abusers (For Cholesterol-mono-TMS) 
Mass chromatograms (MC) using significant fragment ions for cholesterol-5-en such as 
m/z 458,443,329, and 368. 
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Figure 3.23. MS of Testosterone isocaproate-mono-TMS (Rt = 28.16 min) 
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Figure 3.24. MS of nail #04 from anabolic steroid abusers (Rt = 27.83 min) 
(Interfering steroid, cholesterol-4-en-mono-TMS) 
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Figure 3.25. Expanded view of mass spectrum shown in Figure 3.23 
(Rt = 28.16 min) (Specific fragment ions, m/z 458,443,343,207 were detected) 
(2) Testosterone enanthate 
Testosterone enanthate (T-enanthate) was tentatively identified but could not be 
confirmed, although both T-enanthate and T-isocaproate were presumed to be present, 
based on the urine and hair analysis results. 
Data obtained from GC-MS analysis of sample 4 and the data for the standard T 
enanthate are shown in Figures 3.28,3.29 and 3.30 respectively. 
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Figure 3.26. Mass spectrum of standard T-isocaproate-mono-TMS (MW = 458) 
The molecular ion (m/z 458) and M-15 ion (m/z 443) are prominent ions in the 
spectrum. 
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Figure 3.27. MS of nail #04 from anabolic steroid abusers (Rt 28.64 min) 
(Interference mass spectrum, that corresponds to cholesterol-7-en-mono-TMS) 
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Figure 3.28. MC of nail #04 from steroid abuser for T-enanthate-mono-TMS 
The mass spectrum of the peak at 31.74 min looks very similar to that of T 
enanthate. However, the peak should be detected at a retention time of about 30.20 min 
under the GC-MS conditions used. 
The retention time of the peak at 31.74 min is too long. Moreover, the same 
compound was detected in all of the fingernail samples. It appeared to be a compound 
with a molecular weight of 472 having a methyl functional group at the C23-position of 
cholesterol. 
105 
19040404 42709 RT: 31.74 AV: I NL: 6.10E6 
T: (0.0) + CEý =750.00 Ful ms 169.00.693.001 
00 
D 
128.93 
60 M+ 472 
I 
X07 1147.10 14 
367.30 
472.36 
4112 
7187.16 
llu 
I 1 
206.90 
AD. A 
22.13 
383.35 
315.11 
2 =ý 281.04 ý 
471 
ý', 1ýý 
ll 
(+IIý 
. 37 
4 .ý 1ýI 
I'i 
III. ý 
iIl ,. 
I,. 
lI.. 
ýý ice' ' 
4 . 42 
563.38 620.64 661.46 
100 150 200 250 300 350 400 450 500 550 600 650 
m/z 
Figure 3.29. MS of nail #04 from anabolic steroid abusers for T-enanthate-mono-TMS 
(Rt = 31.74 min) 
The molecular ion and M-15 ion appear at (m/z 472) and (m/z 457) respectively. This 
mass spectrum is very similar to that of the standard (Figure 3.30). 
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Figure 3.30. Mass spectrum of T-enanthate-mono-TMS standard (MW = 472) 
A prominent molecular ion appears at m/z 472. 
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3.3.3.4 Quantitative analysis of endogenous steroids 
The calibration curves were prepared with unextracted standards and were nonlinear 
curves, which were fitted using polynomial regression (statistical application package 
of Microsoft Excel) within the range from 0.000 to 0.500 ng/µL for AND, ETIO, 
DHEA, epiAND, epiTEST, and TEST [Figure 3.31]. 
0 2.0 
1.5 
1.0 
Q 0.5 
0.0 
a' 
-0.5 
Concentration of Testosterone (ng/uL) 
No. Conc (ng) Conc (ng/tL) Test/d3-T 
1 0.00 0.0000 0.0058 
2 0.02 0.0050 0.0302 
3 0.05 0.0125 0.0569 
4 0.10 0.0250 0.1035 
5 0.50 0.1250 0.5926 
6 1.00 0.2500 1.1505 
7 2.00 0.5000 1.8854 
Figure 3.31. Calibration curve and GC-MS data for Testosterone-di-TMS 
The correlation coefficients of the curves for AND, ETIO, DHEA, epiAND, 
epiTEST and TEST were 1.0000,0.9999,0.9805,0.9971,0.9988 and 0.9996, 
respectively. When linear regression was used initially instead of polynomial regression, 
the regression line did not fit the data well and the correlation coefficient was much 
lower. 
The limits of detection (LOD, calculated using the statistical application package of 
Microsoft Excel) for AND, ETIO, DHEA, epiAND, epiTEST and TEST were 5.4,13.9, 
0.00 0.20 0.40 0.60 
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7.2,0.4,1.4 and 0.8 pg on column, respectively. 
3.3.3.5. Nail samples 
Five (5) nail samples from anabolic steroid abusers and two (2) nail samples of 
healthy persons were analysed for the identification and determination of endogenous 
anabolic steroids. Norepiandrosterone-d3 (d3-NEA) and testosterone-d3 (d3-TEST) were 
used as internal standards for the quantitative GC-MS analysis of endogenous steroids. 
As shown in Table 3.10, the concentrations of the steroids in nail were extremely 
low compared to plasma and urine. As exceptions, the concentrations of endogenous 
steroids in nail samples 3 and 4 were high compared with other nail samples [Table 3.10]. 
Table 3.10. Concentrations of endogenous steroids in nail samples (pg/mg), 
plasma mL , and urine mL 
Analyte AND ETIO DHEA e iAND e iTEST TEST 
AAS Abusert #I (Nai 4.1 0.0 5.6 3.3 3.0 4.3 
AAS Abuser #2(Nail 4.7 0.0 3.0 1.9 1.5 3.9 
AAS Abuser #3(Nail 9.6 0.0 25.3 14.3 11.0 10.6 
AAS Abuser #4(Nail 12.8 0.0 12.0 6.2 10.9 25.0 
AAS Abuser #5(Nail 1.7 0.0 1.8 0.8 0.6 0.6 
Healthy # 1(Nail) 1.5 0.0 1.4 0.7 0.6 6.5 
Healthy #2(Nail) 8.4 0.0 4.5 1.7 2.6 1.1 
Healthy #1(Plasma) 30322.9 54222.5 11218.3 Trace 222.2 3583.8 
Healthy #2(Plasma) 9923.3 2966.7 100.6 Trace 200.2 196.0 
Note: The concentration of endogenous steroids in nail samples #3 and #4 are high 
compared with other nail samples. AAS = Anbolic Androgenic Steroids 
Tables 3.11-1 - 3.11-3 show the peak areas of selected ion chromatograms of each 
endogenous steroid in nail samples (No.! - No. 8) and of deuterated internal standards. 
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Tab le 3.11-1. Quantitation of endogenos steroids in nail 
N N Nail Sample 
01,8.32 mg o. ame Peak area I. Std area Ratio Total (ng) C (pg/mg) 
1 d3-NEA 44736032 44736032 1.0000 
2 AND 809637 44736032 0.0181 0.0181 2.18 
3 ETIO 
4 DOP 
5 DHEA 256902 239070953 0.0011 0.0060 0.72 
6 epiAND 734927 239070953 0.0031 0.0038 0.46 
7 epiTEST 2010500 239070953 0.0084 0.0208 2.50 
8 d3-TEST 239070953 239070953 1.0000 
9 TEST 8497842 239070953 0.0355 0.0411 4.94 
No N Nail Sample 02,15.10 m . ame Peak area I. Std area Ratio Total (ng) C (pg/mg) 
1 d3-NEA 20535570 20535570 1.0000 
2 AND 619765 20535570 0.0302 0.0302 2.00 
3 ETIO 
4 DOP 
5 DHEA 
6 epiAND 1178585 254627378 0.0046 0.0057 0.38 
7 epiTEST 
8 d3-TEST 254627378 254627378 1.0000 
9 TEST 18032104 254627378 0.0708 0.0819 5.42 
No. Name Nail Sample 03,1.84 m 
Peak area I. Std area Ratio Total (ng) C (pg/mg) 
2 AND 349115 5071 1124 0.0069 0.0069 3.75 
3 ETIO 
4 DOP 
5 DHEA 210808 226908419 0.0009 0.0049 2.66 
6 epiAND 455244 226908419 0.0020 0.0025 1.36 
7 epiTEST 158496 226908419 0.0007 0.0017 0.92 
8 d3-TEST 226908419 226908419 1.0000 
9 "LEST 2421613 226908419 0.0107 0.0124 6.74 
Note: Peak area = area of endogenous steroid peak in mass chromatogram, I. Std area = 
area of internal standard peak, d3-NEA = Norepiandrosterone-d3, d3-Test = 
Testosterone-d3, Total (ng) = total weight in ng of endogenous steroid present, C= 
concentration of endogenous steroids in pg/mg of nail. Numerical values underlined in 
Table 3.11-1 were calculated manually. 
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Tabl e 3.11-2. Quantitation of endogenos steroids in nail 
N N Nail Sample 
04,4.24 mg 
o. ame Peak area I. Std area Ratio Total (ng) C (pg/mg) 
I d3-NEA 19319589 19319589 1.0000 
2 AND 371599 19319589 0.0192 0.0192 4.53 
3 ETIO 
4 DOP 
5 DHEA 905713 327652941 0.0028 0.0153 3.61 
6 epiAND 697974 327652941 0.0021 0.0026 0.61 
7 epiTEST 13590560 327652941 0.0415 0.1026 24.20 
8 d3-TEST 327652941 327652941 1.0000 
9 TEST 45995392 327652941 0.1404 0.1624 38.30 
N N Nail Sample 05,35.9 1 mg o. ame Peak area I. Std area Ratio Total (ng) C (pg/mg) 
I d3-NEA 52861302 52861302 1.0000 
2 AND 1619555 52861302 0.0306 0.0306 0.85 
3 ETIO 
4 DOP 
5 DHEA 3510129 284930111 0.0123 0.0673 1.87 
6 epiAND 677282 284930111 0.0024 0.0030 0.08 
7 epiTEST 1131874 284930111 0.0040 0.0099 0.28 
8, d3-TEST 284930111 284930111 1.0000 
9 TEST I L92514 284930111 0.0161 0.0181 0.50 
N N Nail Sample 06,38.52 mg o. ame Peak area I. Std area Ratio Total (ng) C (pg/mg) 
I d3-NEA 35625802 35625802 1.0000 
2 AND 1005906 35625802 0.0282 0.0282 0.73 
3 ETIO 
4 DOP 
5 DHEA 5039407 301798807 0.0167 0.9140 23.73 
6 epiAND 341196 301798807 0.0011 0.0014 0.04 
7 epiTEST 14'1 868 301798807 0.0049 0.0121 0.31 
8 d3-TEST 301798807 301798807 1.0000 
9 TEST 102621502 301798807 0.3400 0.3933 10.21 
Note: Peak area = area of endogenous steroid peak in mass chromatogram, I. Std area = 
area of internal standard peak, d3-NEA = Norepiandrosterone-d3, d3-Test = 
Testosterone-d3, Total (ng) = total weight in ng of endogenous steroid present, C= 
concentration of endogenous steroids in pg/mg of nail. Numerical values underlined in 
Table 3.11-2 were calculated manually. 
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Tab le 3.11-3. Quantitation of endogenos steroids in nail 
N N Nail Sam 
le 07,20.09 mg 
o. ame Peak area I. Std area Ratio Total (ng) IC (pg/mg) 
1 d3-NEA 340443 340443 1.0000 
2 AND 31279 340443 0.0919 0.0919 4.57 
3 ETIO 
4 DOP 
5 DHEA 24297 842317 0.0288 0.1576 7.84 
6 epiAND 26036 842317 0.0309 0.0381 1.90 
7 epiTEST 42870 842317 0.0509 0.1258 6.26 
8 d3-TEST 842317 842317 1.0000 
9 TEST 12717 842317 0.0151 0.0175 0.87 
N N Nail Sample 08,75.2 8 mg o. ame Peak area i. Std area Ratio Total (ng) C (pg/mg) 
1 d3-NEA 35390471 35390471 1.0000 
2 AND 264097 35390471 0.0075 0.0075 0.10 
3 ETIO 
4 DOP 
5 DHEA 14129134 279165398 0.0506 0.2768 3.68 
6 epiAND 2513360 279165398 0.0090 0.0110 0.15 
7 epiTEST 5129319 279165398 0.0184 0.0455 0.60 
8 d3-TEST 279165398 279165398 1.0000 
9 TEST 6023063 279165398 0.0216 0.0250 0.33 
Note: Peak area = area of endogenous steroid peak in mass chromatogram, I. Std area = 
area of internal standard peak, d3-NEA = Norepiandrosterone-d3, d3-Test = 
Testosterone-d3, Total (ng) = total weight in ng of endogenous steroid present, C= 
concentration of endogenous steroids in pg/mg of nail. Numerical values underlined in 
Table 3.11-3 were calculated manually. 
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3.3.3.6. Blood (plasma) samples 
The concentrations of steroids in plasma samples from two healthy persons were 
measured along with the concentrations of steroids in the fingernails of steroid abusers for 
the purposes of method verification and comparison between the different matrices. The 
concentrations of endogenous steroids in plasma were higher than in nail [Table 3.12]. 
Tab le 3.12. uantitation of endogenous steroids in plasma. 
No N 010304sim07 (plasma) 
. ame Peak area 1. Std area Ratio Total (ng) C (ng/mL) 
1 d3-NEA 271210 271210 1.0000 
2 AND 1460760 271210 5.3861 17.8299 17.8299 
3 ETIO 566059 271210 2.0872 8.4567 8.4567 
4 DOP 
5 DHEA 89098 2276386 0.0391 0.3823 0.3823 
6 epiAND 
7 epiTEST 698526 2276386 0.3069 0.9530 0.9530 
8 d3-TEST 2276386 2276386 1.0000 
9 TEST 591373 2276386 0.2598 0.6783 0.6783 
010304sim06 (plasma) No. Name 
Peak area I. Std area Ratio 1 Total (ng) C (ng/mL) 
2 AND 34344613 2117346 16.2206 53.7210 53.7210 
3 ETIO 8077801 2117346 3.8151 15.4576 15.4576 
4 DOP 
5 DHEA 226985176 27269223 8.3239 81.3811 81.3811 
6 epiAND 
7 epiTEST 13380377 27269223 0.4907 1.5238 1.5238 
91TEST 1 908374151 272692231 3.3311 1 8.6972 1 8.6972 
Note: Peak area = area of endogenous steroid peak in mass chromatogram, I. Std area = 
area of internal standard peak, d3-NEA = Norepiandrosterone-d3, d3-Test = 
Testosterone-d3, Total (ng) = total weight in ng of endogenous steroid present, C= 
concentration of endogenous steroids in ng/mL of plasma. Numerical values underlined 
in Table 3.12 were calculated manually. 
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3.3.3.7. Urine samples 
As for the plasma samples, the concentrations of steroids in urine collected from the 
same two healthy persons were measured along with the concentrations of steroids in 
fingernail from steroid abusers for the sake of comparison [Table 3.13]. In each case, the 
concentrations of endogenous steroids in the urine samples were high compared with 
those in the nail samples. 
However, the following considerations are necessary with respect to the 
experimental procedure used and its effect on steroid concentrations. That is, the steroid 
analytes were extracted from the urine samples with an SPE method, and subsequently 
the steroids were re-extracted after enzyme hydrolysis. Therefore, the recovery of each 
steroid became lower. However, the measured concentrations of the steroids are accurate 
because deuterated internal standard samples were added at the same time, which would 
compensate for losses. 
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Table 3.13. Quantitation of endogenos steroids in urine. 
No. Name 
061103sim5 
Peak area I. Std area Ratio Total (m-0 1C (nu. /mL 
2 AND 99576 24354 4.0887 4.4240 0.8848 
3 ETIO 142112 24354 5.8353 4.3491 0.8698 
4 DOP 
5 DHEA 2307512 7794203 0.2961 0.0710 0.0142 
6 epiAND 664817 7794203 0.0853 0.1098 0.0220 
7 epiTEST 212030 7794203 0.0272 0.0370 0.0074 
8 d3-TEST 7794203, 7794203, 1.0000 
f-97- TEST 659309 7794203 0.0846 0.0681 0.0136 
N N 06 1103sim2 o. ame Peak area I. Std area Ratio Total (-n-g-) C (ng/mL 
I d3-NEA 1342659 1342659 1.0000 
2 AND 1228466 1342659 0.9150 1.7002 0.3400 
3 ETIO 1529742 1342659 1.1393 1.7969 0.3594 
4 DOP 
5 DHEA 18756211 189755389 0.0988 0.0516 0.0103 
6 epiAND 4886584 189755389 0.0258 0.0492 0.0098 
7 epiTEST 7175217 189755389 0.0378 0.0438 0.0088 
8 d3-TEST 189755389 189755389 1.0000 1 L 
9 TEST 12277462 189755389 0.0647 0.0548 - 0.0110 
Note: Peak area = area of endogenous steroid peak in mass chromatogram, I. Std area = 
area of internal standard peak, d3-NEA = Norepiandrosterone-d3, d3-Test = 
Testosterone-d3, Total (ng) = total weight in ng of endogenous steroid present, C= 
concentration of endogenous steroids in ng/mL of urine. Numerical values underlined in 
Table 3.13 were calculated manually. 
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3.3.4. Results obtained 
The endogenous anabolic steroids androsterone (1.5-12.8 pg/mg), etiocholanolone, 
dehydroepiandrosterone (1.4-25.3 pg/mg), epiandrosterone (0.7-14.3 pg/mg), 
epitestosterone (0.6-11.0 pg/mg), and testosterone (0.6-25.0 pg/mg) were identified and 
quantified in fingernail samples. The concentration of each steroid in the fingernail 
clippings was extremely low compared with the concentrations in urine and blood 
(plasma) as shown in parentheses. In general, higher concentrations of testosterone were 
associated with higher concentrations of androsterone, dehydroepiandrosterone, 
epiandrosterone and epitestosterone. In particular, the concentrations of endogenous 
anabolic steroids were extremely high in the fingernail clippings of the anabolic steroid 
abusers who also showed high concentrations of testosterone in urine. 
The presence of exogenous (synthetic) anabolic steroids was investigated using gas 
chromatography - mass spectrometric analysis of fingernail clippings from five anabolic 
steroid abusers. As a result of these qualitative analyses, it was found that testosterone 
isocaproate and testosterone enanthate were difficult to detect. Although the analytical 
results provided some evidence for the presence of anabolic steroids in the samples from 
steroid users, including testosterone and testosterone esters at low concentrations, it has 
not yet been possible to confirm this due to interference from other endogenous 
substances. Further work is necessary to clean up the initial extracts and to resolve the 
interference. 
As a result of this study, a fundamental analytical method was obtained for anabolic 
steroids in fingernail clippings by GC-MS along with initial analytical data. However, 
more work is needed in future on the analysis of nail samples from a larger population of 
doping steroid abusers to overcome the problems identified here. 
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3.4. Conclusions 
Qualitative and quantitative analyses of anabolic steroids in nail samples were 
successfully carried out by GC-MS using the cryogenic grinding method for sample 
preparation. Trimethylsilyl (TMS) derivatives of doping anabolic steroids were used for 
sample preparation for GC-MS analysis. An amended method was found to work well 
for the preparation of the TMS derivatives compared with methods described in 
published articles. This overcame the problem of dissolving the catalyst, ammonium 
iodide in the silanising reagent, MSTFA and was good for trimethylsilylation of doping 
steroids having enolic, ketonic and sterically hindered hydroxy groups because of 
complete mixing of the reagents. As a result, endogenous anabolic androgenic steroids 
(androsterone, etiocholanolone, dehydroepitestosterone, epiandrosterone, epitestosterone, 
and testosterone) were identified and determined by GC-MS in the selected ion 
monitoring mode. 
Exogenous (synthetic) anabolic steroids from nail samples of anabolic steroid 
users could not be detected though testosterone isocaproate and testosterone enanthate 
were tentatively identified. A peak appeared in the nail extracts at the same retention time 
as that of a reference standard of testosterone isocaproate. It was not possible to confirm 
its presence due to the co-elution of an interfering component, although the mass 
spectrum of the peak corresponded to the mass spectrum of the reference standard. A 
similar result. was obtained with respect to the identification of testosterone enanthate. If 
high-resolution GC-MS, GC-MS-MS or GC-MS" analysis were used along with 
deuterated internal standards (deuterated testosterone esters), the identification of these 
dubious peaks might be able to be confirmed. 
In general, endogenous steroid concentrations in nail were low, in the pg/mg range. 
However, it was noted that the concentrations of endogenous steroids in two nail samples 
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from steroid abusers were much higher than those in other samples. The 
testosterone/epitestosterone ratio was high in these two samples compared with the other 
samples in this study. The reason for this is not known, as concentrations of endogenous 
steroids are expected to decrease when exogenous anabolic steroids are administered, the 
basis of the current urine test for anabolic steroid abuse. 
Qualitative and quantitative analyses of androgenic steroids in the urine and plasma 
samples of healthy volunteers were carried out at the same time. As a result, in general, 
elevated concentrations of testosterone in nail were positively associated with high 
concentrations in plasma and urine. 
Nail remains a potential, but still to be confirmed, alternative biological specimen 
to hair for the detection of past exposure to doping steroids. It will be necessary to 
analyse nail samples from a much larger population and collect a statistically-significant 
set of data for elucidation of these unresolved problems. Moreover, it will be necessary to 
analyse conjugated steroids in the fingernail as well as free steroids. Further 
methodological developments will be needed to improve the clean-up of nail extracts to 
reduce the effects of interferences on the analysis of steroids. 
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4. Analysis of Opium Alkaloids using Pyrolysis GC-MS and Matrix 
Assisted Laser Desorption Ionisation - Time of Flight - Mass 
Spectrometry. 
This study was conducted in the Identification Research Laboratory, National 
Research Institute of Police Science, Tokyo, Japan, during a period of study at an 
external institution approved by the Faculty of Science, University of Glasgow. 
A. Analyses of Opium Alkaloids using Pyrolysis GC-MS 
4.1. Introduction 
Gas chromatography-mass spectrometry (GC-MS) has been the most commonly 
used method for the analysis of opium alkaloids. When opium alkaloids in fingernail 
clippings are analysed, the analytical procedure necessarily involves GC-MS after 
extraction of the alkaloids from the fingernail samples. However, it is possible that street 
heroin residues in fingernail samples can be directly analysed by pyrolysis GC-MS (Py- 
GC-MS). Moreover, the analytical procedure for street heroin in nail would be 
simplified, and there is the simultaneous possibility of being able to apply the method to 
the analysis of seized street heroin. 
Published articles on the analysis of opium alkaloids by Py-GC-MS are extremely 
few in number [183,184,185,186,187] though many other analytical methods have been 
used, as described in the section on the analysis of street heroin in Chapter 2. 
The most important reason is that thermal analysis instruments are not yet 
widespread in the field of forensic science. In the references of many Py-GC-MS papers 
concerning opium alkaloids, few report that the temperature of the thermal degradation is 
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correctly controlled. In this study, Py-GC-MS of opium was achieved by using both the 
Curie-point pyrolyser and the double shot pyrolyser, as well as a normal gas 
chromatographic instrument that allowed the temperature of thermal degradation to be set 
to the optimum value. 
There were two purposes in this Py-GC-MS study. The first was to prove whether it 
is possible to analyse opium alkaloids in nail directly using Py-GC-MS without extracting 
the drug from the fingernail. 
The second was to reduce the weight of the nail sample needed for the analyses of 
opium alkaloids by thermal analysis. In the work carried out, fingernail samples 
containing opium alkaloids were not available, and spiked samples were prepared by 
adding opium alkaloids to powdered fingernail clippings instead. 
As a result, it was found that opium alkaloids could be analysed by Py-GC-MS. 
There was no thermal degradation of the alkaloids if they were converted to TMS 
derivatives and excellent Py-GC-MS analysis could be performed. 
4.2. Methods and Materials - Samples 
1) Turkish opium 
2) Unknown opium 
The opium samples were obtained from stock of the Department of Forensic 
Medicine and Science, University of Glasgow. The opium was dissolved with methanol 
and a working solution with a concentration of 1.0 µg/mL of opium was prepared. 
3) Nail clippings 
Nail clipping samples were obtained from healthy volunteers who were non-opiate 
users. 
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4.3. Methods and Materials - Instruments 
The following instruments were used: 
1) HP6890 GC + HP5973N MSD (HP, USA); 
2) HP6890 GC + HP5973N MSD with Double-shot pyrolyser, model PY-2020D, 
(Frontier Lab, Japan); 
3) Shimadzu GC-MS QP-5000 (Shimadzu, Japan) with Curie-point pyrolyser 
(Japan Analytical Industry Co., Japan). 
4.4. Pyrolysis GC-MS without pyrolyser (injection port of gas chromatograph) 
4.4.1. Principle 
The analyte is decomposed by heating in the injection port of gas chromatograph 
(GC). 
4.4.2. Gas chromatography - mass spectrometric (GC-MS) analysis 
Two (2) µL of a methanol solution of the opium (2 µg) was injected into the gas 
chromatograph - mass spectrometer (GC-MS). 
4.5. Pyrolysis GC-MS with pyrolyser (double shot furnace) 
4.5.1. Principle 
Figure 4.1 shows the main body of the double-shot pyrolyser. Figure 4.2 shows 
the state to set up the pyrolyser and the controller of the double-shot pyrolyser in the 
Hewlett Packard GC. 
As shown in Figure 4.3, the crucible, made of stainless steel, is set up in the upper 
part of the furnace and kept at a constant temperature. A sample of about 0.1 mg in 
weight is put in this crucible. The crucible falls into the furnace and the sample is 
decomposed by heating. The generated gas is introduced into the GC for six (6) sec and 
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analysed. The injection port of gas chromatograph (GC) is modified to meet the 
pyrolyser, but the split ratio (10: 1) of the GC is the same as in conventional gas 
chromatography. 
Figure 4.1. Double-shot pyrolyser, model PY-2020D 
Figure 4.2. HP GC-MS fitted with Frontier Lab's pyrolyser 
(model: Thermal analysis system 2020) 
Crucible 
Electric heater 
Furnace 
Direct connection with the 
injection port of the GC 
Figure 4.3. Outline of the double shot pyrolyser 
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4.5.2. Sample preparation for pyrolysis GC-MS 
300 µL of a solution of ethylmorphine hydrochloride in methanol (1.01 µg/µL) and 
300 µL of a solution of morphine in methanol (1.06 µg/µL) were added to 15.3 mg of 
powdered fingernail clippings in a micro-test tube. 
The nail-methanol mixtures were concentrated and dried using a rotary evaporator 
(Buchi, Germany). The sample therefore contained ethylmorphine (20 µg) and morphine 
(20 µg) respectively per milligram of fingernail powder. 
The nail powder was obtained by pulverising nail clippings with a cryogenic 
milling device (Japan Analytical Industry, model JFC-300, Tokyo, Japan), for 5 min 
under liquid nitrogen, after the samples had been decontaminated by the method 
described in Chapter 2. 
4.5.3. Pyrolysis GC-MS analyses 
0.3-2.0 mg of powdered nail samples was analysed by Py-GC-MS. 
4.6. Pyrolysis GC-MS with Curie point pyrolyser 
4.6.1. Principle 
As shown in Figure 4.4, the sample wrapped in electromagnetic foil is set up in the 
high frequency induction furnace. 
When the high frequency is irradiated on to the sample, the electromagnetic foil 
reaches a constant high temperature in an extremely short time (sec). The temperature 
reached depends on the type of electromagnetic foil (Table 4.1). 
The heat generated decomposes the sample. The generated gas is introduced into 
the injection port of the GC by the introduction pipe. 
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Sample wrapped in electromagnetic foil 
Introduction pipe to the GC 
Emission gas 
To injection 
port of the GC 
High frequency induced furnace 
Figure 4.4. Outline of the Curie point pyrolyser 
Table 4.1. Curie point temperatures of pyrolysis 
probes 
Curie point temperature (°C) Composition 
1040 Co 
920 Co, Fe 
764 Fe 
740 Fe, Other 
670 Fe, Other 
650 Stainless 
590 Co, Ni 
500 Co, Ni 
485 Ni, Other 
445 Ni, Fe, Other 
386 Ni, Fe, Other 
358 Ni, Other 
280 Ni, Cu 
255 Ni, Cu, Other 
235 Ni, Cu, Other 
220 Ni, Cu, Other 
The introduction pipe is kept at a constant high temperature, and prevents the 
emission gas being adsorbed. 
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4.6.2. Sample preparation for pyrolysis GC-MS 
The samples used were the same sample as for Curie point Py-GC-MS. 
4.7. Results and Discussion 
4.7.1. Pyrolysis GC-MS without pyrolyser (Thermal degradation at injection port of 
the GC) 
(a) Free (base) opium alkaloids 
Figure 4.5 shows total ion chromatogram (TIC) of the GC-MS analysis of 2 µg of 
the methanol extracts of Turkish opium. 
Codeine, morphine, and thebaine were determined as the main morphine alkaloids 
present as shown in Table 4.2. The quality parameter in Table 4.2 shows degree (%) of 
agreement obtained between the sample spectrum and the library spectrum in a computer 
search of the mass spectral database from Hewlett Packard Co. 
Similarly, Figure 4.6 shows the TIC from GC-MS of 2 µg of the methanol extracts 
of the unknown opium. Codeine, morphine, and thebaine were also determined to be the 
main morphine alkaloids present, as shown in Table 4.3. 
(b) Trimethylsilylated opium alkaloids. 
To examine the thermal stability of the morphine alkaloids during GC, the TMS 
derivatives were analysed using the same GC-MS conditions (Figure 4.7). 
Trimethylsilylated opium was prepared by reacting opium with N, O-bis 
(trimethylsilyl)trifluoroacetamide (BSTFA) containing 1% of dimethylchlorosilane 
(DMCS) at 60 °C for 30 min. As shown in Table 4.4, the pyrolysis compounds were 
detected with a higher degree of certainty compared with Table 4.1. 
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Figure 4.5. Total ion chromatogram (TIC) of Turkish opium (2 µg) 
Table 4.2. Detected opiates and retention times (Turkish opium) 
Peak 
No. Rt (min) Compound 
Ions used for 
identification 
Quality 
/o 
1 6.041 Meconin 165,124,147 52 
2 6.673 Hydrocotarnine 220, M, 178 76 
3 12.109 Codeine 222,162,229 55 
4 12.541 Morphine 2 5,162,215 0 
5 12.882 Thebaol 20,175 89 
6 13.223 Thebaine 111,255,296 70 
7 13.323 Thebaine 311,255,296 78 
8 15.520 Papaverine 324,338, M 99 
9 19.020 Noscapine 220,205 64 
Notes: Rt = Retention time, Quality (%) = Match (% fit) of mass spectrum between 
sample and library spectrum. Bold, italic and underline shows molecular ion (m/z). 
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Figure 4.6. TIC of GC-MS (Unknown opium, 2 µg) 
Table 4.3. Detected opiates and retention times (Unknown opium) 
Peak 
No. 
Rt 
min 
Compound Ions used for identification 
Quality 
(%) 
1 6.089 Meconin 165, M, 147 38 
2 6.756 Hydrocotarnine 220,221,178 64 
3 12.177 Codeine 222,162,229 98 
4 12.578 Morphine 285,162,215 94 
5 13.290 Thebaine 111,255,296 86 
6 13.401 Thebaine 311,255,296 50 
7 15.607 Papaverine 324,338,332 25 
8 19.178 Noscapine 220,205 10 
Notes: Rt = Retention time, Quality (%) = Match (% fit) of mass spectrum between 
sample and library spectrum. Bold, italic and underline shows molecular ion (m/z). 
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Figure 4.7. TIC of GC-MS (TMS-Turkish opium) 
Table 4.4. Retention time and matching rate of TMS-Turkish opium 
(10 of TMS-Turkish opium) 
Peak 
No. Rt (min) Compound 
Ions used for 
identification 
Quality 
(%) 
1 12.571 Codeine-TMS IZI, 234,313 98 
2 13.002 Morphine-di-TMS 122,41,401 99 
3 13.223 Thebaine X11,255,296 83 
4 13.323 Thebaine 311,255,296 99 
5 15.529 Papaverine 324,338,112 99 
6 19.020 Noscapine 220,205 72 
Notes: Rt = Retention time, Quality (%) = Match (% fit) of mass spectrum between 
sample and library spectrum. Bold, italic and underline shows molecular ion (m/z). 
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4.7.2. Pyrolysis GC-MS with double shot pyrolyser 
The thermal stability of opium free bases and their derivatives, including acetyl and 
trimethylsilyl derivatives, were examined. 
4.7.2.1. GC-MS analyses of free opium alkaloids 
A quantity of opium weighing about 1.0 mg was analysed by Py-GC-MS as shown 
in Figures 4.8 and 4.9 and Tables 4.5 and 4.6. The pyrolysis temperature was 350 °C. 
This temperature was set as an optimum temperature of pyrolysis following trials of 
a range of temperatures. The pyrolysis temperature in the injection port of the GC was 
also set at 280 °C as an optimum temperature. Therefore, it can be confirmed that the 
sample was decomposed in pyrolysis GC-MS analysis if a pyrolyser was used. 
3,5-dimethoxy-4,5-epoxyphenanthrene was detected as a product of thermal 
degradation from both the Turkish and the unknown opium. Also, Neopine (ß-codeine) 
was detected as an interesting compound from Turkish opium. 
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Figure 4.8. TIC of Py-GC-MS (about 1 mg Turkish opium) 
Table 4.5. Detected opiates and retention time by Py-GC-MS 
(Turkish opium ) 
Peak 
No. Rt (min) Compound 
Ions used for 
identification 
Quality 
/o 
1 5.170 Meconin 165,194,147 99 
2 5.593 ? 
3 6.007 H drocotarnine 220,2R, 178 97 
4 10.544 ? 
5 11.052 3,6-DiMeO-4,5- 
e ox henanthrene 
212 98 
6 11.833 Codeine 162,229 99 
7 12.012 Neopine ß-Codeine 222,254,285 94 
8 12.247 Morphine ? L, 162,215 99 
9 12.360 MW 313? 
10 12.473 MW 313? 
11 12.624 Thebaol 290,175 99 
12 12.859 MW 317? 
13 12.981 Thebaine 311,255,296 89 
14 13.085 Thebaine 311,255,296 96 
15 13.188 MW 313? 
16 15.287 Pa averine 324,338,332 99 
17 
_1 
8.431 Nosca ine 220,205 
Notes: Rt = Retention time, Quality (%) = Match (% fit) of mass spectrum between 
sample and library spectrum. Bold, italic and underline shows molecular ion (m/z). 
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Figure 4.9. TIC of Py-GC-MS (Unknown opium) 
Table 4.6. Detected opiates and retention time by Py-GC-MS (Unknown opium) 
Peak 
No. 
Rt 
(min) 
Compound Ions used for 
identification 
Quality 
(%) 
1 3.264 4-Hydroxy-benzeneethanol 107,118 90 
2 5.871 Meconin 165, M, 147 
3 6.530 Hydrocotarnine 220,221,178 95 
4 11.122 3,6-DiMeO-4,5-epoxyphenanthrene 2 86 
5 11.875 Codeine 222,162,229 98 
6 12.280 Morphine 2$S, 162,215 99 
7 12.657 Thebaol 2Q3., 175 7 
8 13.005 Thebaine I11,255,296 9 
9 13.108 Thebaine 311,255,296 5 
10 15.282 Papaverine 324,338,12 49 
11 18.426 Noscapine 220,205 42 
Notes: Rt = Retention time, Quality (%) = Match (% fit) of mass spectrum between 
sample and library spectrum. Bold, italic and underline shows molecular ion (m/z). 
TIC: UNKNWOPM. D 
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4.7.2.2. Acetylated opium alkaloids in nail 
Samples were prepared in which ground fingernail was treated with the acetylated 
derivative of opium, to simulate fingernail samples containing street heroin. There were 
two aims. The first was to examine the thermal stability of the acetyl derivative. The 
second was to establish the amount of fingernail that is required for analysis. 
The acetylation of opium was carried out with opium and acetic anhydride using 
pyridine as catalyst at 60 °C for 30 min. The acetylated opium was dissolved with ethyl 
acetate and mixed with decontaminated pulverised nail clippings using a rotary 
evaporator. As a result, pulverised nail contained about 500 ng of acetylated opium per 
milligram was obtained. 
Figure 4.10 shows the TIC from the pyrolysis GC-MS of 0.3 mg of the blank nail 
sample. The peak at a retention time of about 7.7 min is dibutyl phthalate (DBP, CI6H2204 
= 278.35). 
Abundance 
TIC: NAILBLNK. O 
1 80000 
160000 
140000 
ýýýýyfý IM1yt 
MTT' 
1 20000 
1 00000 1 
eoooo± 
4500 IIfy 
400:: 
i 
20000+ 
OM 
2.00 4.00 6.00 8.00 1 O. Ot12. Ot14. Ot'16. Ot1 6. OC20. OC22. OCß4. Ot2a. 
Ot26.00 
Tlrrfý--s 
Figure 4.10. TIC of Py-GC-MS (0.3 mg blank nail) 
Figure 4.11 shows the TIC from Py-GC-MS of a nail sample containing 500 ng of 
the acetylated unknown opium. Tables 4.7 and 4.8 show retention times (min) and 
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library search fit factors (%) of mass spectra of the detected compounds of the unknown 
and the acetylated Turkish opium, respectively. In Tables 4.7 and 4.8, the thermal 
decomposition compound, 3,6-dimethoxy-4,5-epoxy-phenanthrene was detected. 
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Figure 4.11. TIC of Py-GC-MS (500 ng of acetylated unknown 
opium, 0.2 mg nail) 
Table 4.7. Retention time and library search fit factor of acetylated unknown opium 
Peak 
No. Rt (min) Compound 
Ions used for 
identification 
Quality 
/o 
1 5.838 6,7-DiMeO-isobenzofuranone 1$! 1 98 
2 6.148 4,5-DiMeO-isobenzofuranone-1,3-dione 20 97 
3 6.506 Hydrocotarnine 220, ? J, 1,178 96 
4 11.099 3,6-DiMeO-4,5-epoxyphenanthrene 2.2 95 
5 12.633 Thebaol 20,175 89 
6 12.906 6-Acetylcodeine 34.1,282,229 99 
7 13.094 Thebaine 311,255,296 94 
8 13.885 Heroin 327,30,308 99 
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9 15.268 Papaverine 324,338,132 10 
10 18.412 Noscapine 220,205 38 
Quality (%) = Match (% fit) of mass spectrum between sample and library spectrum. 
Bold, italic and underline shows molecular ion (nz/z). 
Table 4.8. Retention time and library search fit factor of acetylated Turkish opium 
Peak 
No. 
Rt 
min 
Compound 
Ions used for 
identification 
Quality 
1 10.986 3,6-DiMeO-4,5-epoxyphenanthrene 2U 95 
2 12.586 Thebaol 2l3,175 99 
3 12.868 6-Acetylcodeine M, 282,229 99 
4 12.953 6-Monoacetylmorphine 287,340, . Q2 95 
5 13.066 Acetylthebaol 226 98 
6 13.885 Heroin 327,3Q, 308 99 
7 15.278 Papaverine 324,338, .3Q 99 
8 18.421 Noscapine 220,205 53 
Notes: Rt = Retention time, Quality (%) = Match (% fit) of mass spectrum between 
sample and library spectrum. Bold italic and underline shows molecular ion (m/z). 
4.7.2.3. Reproducibility and thermal stability of opium alkaloids 
Sample preparation: 
Nail samples were prepared containing 20 µg/mg and 20 ng/mg each of 
ethylmorphine-HCI and morphine respectively using a rotary evaporator. 
The nail samples (1-2 mg) were used for quantitative analysis by Py-GC-MS and 
GC-MS as TMS derivatives and underivatised samples. 
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Ethylmorphine (C19H23N03 = 313.40), morphine (CH, 9NO3 = 285.34) and their 
TMS derivatives were analysed by quantitative analysis and thermal stability as shown in 
Figure 4.12. 
4.7.2.4. Quantitative analysis 
(a) Reproducibility of free morphine alkaloids 
Tables 4.9 and 4.10 show analytical data for TMS derivatives of ethylmorphine 
(I. Std) and morphine. 
Nail samples (containing 20.0 µg/mg each of morphine and ethylmorphine-HC1) 
were added directly to the Py-GC-MS sample holder, and the Py-GC-MS was carried out. 
Reproducibility of the peak area ratio of morphine to ethylmorphine was poor as shown in 
Table 4.9. 
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Figure 4.12. Mass chromatograms of Morphine/Ethylmorphine 
(20 µg each), nail 1.0 mg 
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Table 4.9. Quantitative analysis of morphine in nail by Py-GC-MS 
File Name 
Py-GC-MS 
Nail Wt. 
(mg) 
Intensity 
m/z 313 
Intensity 
m/z 285 
Peak Area 
Ratio (%) 
Et-Morp. 
Rt (min) 
Morphine 
Rt (min) 
011001. d 1.2 0 0 0.00 0.000 0.000 
011002. d 1.7 46411 192900 24.06 12.163 12.265 
011003. d 1.0 43067 1027429 4.19 12.169 12.270 
011004. d 1.2 52071 415290 12.54 12.169 12.270 
Notes: Rt = Retention time, Et-Morp. = Ethylmorphine. 
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(b) Reproducibility of trimethylsilylated morphine alkaloids 
10 µL of BSTFA containing 1% of DMCS and 20 µL of dimethylformamide was 
added to the nail and heated for 30 min at 60 T. 
One (1) µL of trimethylsilylated sample was injected into the HP GC-MS. The 
intensity of mass chromatogram was high and reproducibility was good, as shown in 
Table 4.10. The reproducibility of data was 98.6% (n=4). 
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Figure 4.13. MC of Ethylmorphine-TMS/Morphine-di-TMS (1.47 µg) 
Table 4.10. Quantitative analysis of TMS derivatives 
File Name 
GC-MS 
Nail Wt. 
(mg) 
Intensity 
m/z 429 
Intensity m/z 
385 
Peak Area 
Ratio (%) 
Et-Morp. 
Rt (min) 
Morphine 
Rt (min) 
021001. d 2.2 13 863392 13741395 100.89 12.867 13.024 
021002. d 1.7 14490133 14334135 101.09 12.836 12.998 
021003. d 1.8 17779749 18279387 97.27 12.867 13.029 
021004. d 1.4 16936573 17815775 95.07 12.868 13.020 
Notes: Rt = Retention time, Et-Morp. = ttnyimorpnine. 
7 v. 60 1 1.00 1 I. 60 ý1. w I-. - . -..... . -....... . -...... . -....., 
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(c) Reproducibility of trimethylsilylated morphine alkaloids by Py-GC-MS 
2 µL of the same sample solution was injected into the Py-GC-MS sample holder. 
As shown in Table 4.11, reproducibility of the peak area ratio was poor compared with 
conventional GC-MS. 
Table 4.11. Quantitative analysis of TMS derivative 
File Name 
Py-GC-MS 
Nail Wt. 
(mg) 
Intensity 
m/z 429 
Intensity 
m/z 385 
Peak Area 
Ratio (%) 
Et-Morp. 
Rt (min) 
Morphine 
Rt (min) 
011010. d 2.2 3262 2971 109.79 12.639 12.809 
011012. d 1.7 7024 6174 113.77 12.648 12.813 
011013. d 1.8 28290 17082 165.61 12.643 12.809 
011014. d 1.4 57264 41906 136.65 12.643 12.809 
Notes: Rt = Retention time, Et-Morp. = Ethylmorphine. 
(d) Reproducibility of low concentrations of trimethylsilylated morphine 
alkaloids by GC-MS 
10 µL of BSTFA containing 1% of DMCS and 20 µL of dimethylformamide were 
added to nail samples (containing 20.0 ng/mg each of morphine and ethylmorphine-HCI) 
and heated for 30 min at 60 T. One (1) µL of trimethylsilylated sample was injected into 
the HP GC-MS. 
There was reproducibility in some degree though the intensities of the mass 
chromatogram were low, as shown in Table 4.12. 
(e) Reproducibility of morphine alkaloids by Curie point Py-GC-MS 
There was no reproducibility of morphine alkaloids regarding Curie point Py-GC- 
137 
MS at the optimum pyrolysis temperature. Pyrolysis temperature and temperature of the 
introduction pipe were 341 °C and 260 °C, respectively. If a newer model (directly 
connected to the injection port of the GC instrument) had been used for the Py-GC-MS, 
the reproducibility might have been better. 
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Figure 4.14. MC of Morphine-di-TMS/Ethylmorphine-TMS 
(each 1.33 ng) 
Table 4.12. Quantitative analysis of TMS derivatives 
File Name 
GC-MS 
Nail Wt. 
(mg) 
Intensity 
m/z 429 
Intensity 
m/z 385 
Peak AreaE 
Ratio (%) 
Morp. 
Rt (min) 
Morphine 
Rt (min) 
031001. d 2.1 194509 229320 84.82 12.841 12.994 
031002. d 2.0 10508 11853 88.65 12.828 12.985 
031003. d 2.2 17075 14335 119.11 12.836 12.989 
031004. d 2.0 15445 14524 106.34 12.836 12.989 
Notes: Rt = Retention time, Et-Morp. = Ethylmorphine. 
1 on 385.00 (384.70 to 385.70): 031004. o 
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4.8. Conclusions 
1) Py-GC-MS analyses that assumed the availability of a minimum amount of nail sample 
were carried out. The pyrolysis GC-MS was performed for the analysis of illicit opioids 
in nail clippings using GC-MS combined with several types of pyrolyser. The optimum 
temperature for pyrolysis GC-MS of opium using the double shot pyrolyser (Frontier 
Lab Co., Japan) was 350 T. and reproducible data was obtained. 
2) Good analytical data were not obtained with the Curie point pyrolysis GC-MS 
instrument because of adsorption and thermal degradation of analytes in the interface 
pipe leading to the injection port of the gas chromatograph. Morphine was decomposed 
by pyrolysis as shown Tables 4.1-4.4 and Figures 4.5-4.6, and Figures 4.8-4.9. 
However, TMS derivatives of the morphine alkaloids were not decomposed [Figure 4.7]. 
3) Minor components of opium such as Meconin, Hydrocotarnine, Neopine, Thebaine 
and Thebaol were detected in the opium. These compounds could not be detected in nail 
clippings of heroin abusers. 
4) The reproducibility of the extraction rate of morphine was 98.6% (n=4), when the TMS 
derivative was used (Table 4.10). However, the reproducibility of the extraction rate of 
morphine was poor when the TMS derivative of low concentrations of morphine was 
used (Figure 4.14 and Table 4.12). There was no reproducibility of the extraction rate of 
morphine when no derivative of morphine was used. 
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B. Analysis of Morphine Alkaloids using Matrix Assisted Laser Desorption 
Ionisation-Time of Flight-Mass Spectrometry 
4.9. Introduction 
The analysis of street heroin is equivalent to the analysis of opium alkaloids. 
However, the analysis of street heroin in urine and blood becomes complex because of the 
presence of metabolites and impurities besides the opium alkaloids themselves. In 
addition, the amount of the fingernail sample available becomes a problem in opium 
alkaloid analysis in the fingernail. 
The mass spectrometry is the most excellent method of identifying ultra trace 
amounts of chemical compounds. After opium alkaloids are extracted from fingernail 
clippings, GC-MS analysis is carried out to identify the morphine alkaloids which are 
present. 
The smallest amount of fingernail clipping is available for the GC-MS analysis and 
extraction of the analyte is necessary. The sensitivity of detection and the resolution of 
the mass spectrometer coupled with laser excitation are high. Moreover, the analyte does 
not need to be separated as in GC analysis. 
In this study, it was intended to assess the possibility of analysing trace amounts of 
opium alkaloids in small samples of fingernail collected directly from the finger with a 
TOF-MS instrument. The results given below showed that an extremely small quantity of 
morphine alkaloids could be easily identified with high sensitivity by MALDI-TOF-MS 
without prior separation of impurities. 
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4.10. Methods and Materials 
4.10.1. Samples 
Morphine, ethylmorphine hydrochloride (I. Std), methanol extracts of opium 
(Turkish), methanol extracts of opium (unknown origin), and cocaine were used as test 
samples. 
The MALDI matrix was a-cyano-4-hydroxycinnamic acid (CHCH, C10H7NO3 = 
189.17) 
4.10.2. Instrumentation 
The Matrix Assisted Laser Desorption Ionisation-Time of Flight-Mass 
Spectrometry (MALDI-TOF-MS) was a Voyager System model 4181 from Perkin 
Elmer Biosystems (USA). 
4.10.3. Principle of MALDI-TOF-MS 
As shown in Figure 4.15, when a sample and matrix mixture was irradiated with a 
nitrogen laser emitting light at 337 nm, ions are generated. Mass spectrometry is carried 
out by introducing the ions into a mass spectrometer of the time of flight (TOF) type. 
2,5-dihydroxybenzoic acid (C7H604 = 154.13), 2,6-dihydroxyacetophenone 
(C8H803 = 152.15) and CHCH, etc. are typically used as the matrices. 
Compounds with high polarity, which promote the excitation of ions, are suitable as 
a matrix. The TOF-MS has extremely high resolution and is chiefly used in fields related 
to biochemistry, such as peptides and proteins having high molecular weights. 
In this research, an assessment was made of whether the TOF-MS can also be 
applied to opium alkaloids with low molecular weights. 
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Irradiation of N2 gas Laser (337 nm) Mass spectrometer 
: "; 
f .. % 
" Generation of ions 
. f. ".. 
" "f. 
Sample + Matrix 
Sample holder (Stainless steel) 
Figure 4.15. Principle of MALDI-TOF-MS 
4.10.4. Sample preparation 
A trace amount of the sample was collected in the stainless steel sample holder, and 
the sample was mixed with CHCH as the matrix. CHCH is generally used for the 
analysis of peptides and glycopeptides. 
4.11. Results and Discussion 
4.11.1. Morphine 
As shown in Figure 4.16, the (M+1)+ ion of morphine (CH19N03 = 285.34), m/z 
286 was identified as the base peak ion. Other ions such as m/z 294,379 were 
background ions (see Figure 4.21). 
4.11.2 Ethylmorphine 
Similarly, the (M+1)+ ion of ethylmorphine (C19H23NO3 = 313.40), m/z 314 was 
recognised as base peak ion as shown in Figure 4.17. Other ions such as m/z 212,294, 
379 were background ions respectively (see Figure 4.21). 
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Figure 4.16. MALDI mass spectrum of Morphine 
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4.11.3. Opium extracts (Turkish) 
Figure 4.18 shows the mass spectrum of Turkish opium extracted with methanol. 
The ions at mz 286,300,340, and 414 are (M+1)+ ions of morphine, codeine (C18H21N03 
= 299.36), papaverine (C20H21NO4 = 339.38), and noscapine (C22H23NO7 = 413.43), 
respectively. 
In addition, ions at m/z 220,221 and 222 were recognised as the (M-1)', M+, and 
(M+1)+ ions of hydrocotarnine (C12H, SN03 = 221.31) respectively. The M' 
ion of thebaol 
(C16H1403 = 254.29) was also identified at m/z 254. A fragment ion could be detected at 
m/z 253 that is the (M+1)+ ion of 3,6-dimethoxy-4,5-epoxyphenanthrene (C16H1203 = 
252.27). 
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Figure 4.18. MALDI MS of extract from Turkish opium 
6.5E+4 
4.11.4. Extracts of opium of unknown origin 
Figure 4.19 similarly shows the mass spectrum of an extract with methanol of 
opium of unknown country. The ions at m/z 286,300,340,414,312, and 255 are (M+1) 
+ ions of morphine, codeine, papaverine, noscapine, thebaine (C19H21NO3 = 311.37) and 
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thebaol, respectively. 
In addition, ions at m/z 220,221,222 were recognised as the (M-1)+, M, and 
(M+1)+ ions of hydrocotarnine (C12H1SNO3 = 221.31), respectively. The M+ ion of 
thebaol (C16H1403 = 254.29), m/z 254 was also recognised. The ion at m/i 253 is the 
(M+1)+ ion of 3,6-dimethoxy-4,5-epoxyphenanthrene (C, 6H1203 = 252.27). 
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Figure 4.19. MALDI mass spectrum of opium of unknown origin 
4.11.5. Cocaine 
0 0 
Figure 4.20 shows the MALDI mass spectrum of cocaine. The (M+1) + ion of 
cocaine (CH21NO4 = 303.36) is at m/z 304. 
4.11.6. a-cyano-4-hydroxycinnamic acid 
The (M+1)+ ion of a-cyano4-hydroxycinnamic acid (C10H7NO3 = 189.17) was 
detected at m/z 190 as shown in Figure 4.21. 
145 
1001 
90- 
Spec #1[BP = 190.2,64005] 
190.1500 
164.16P'J 11 
II 304.2821 
$. 4E+4 
801 
701 
601 
60' 
K1 
40, 
301 
20+ 
101 
60 
Spec #1[BP =172.1,35000] 
1001 172.1480 294.2150 
212.1513 
90" 
164.1746 
379.2508 
80 
146.1 514 191.1 
h 
70 
122.1 86 
60' 
60.1119 
295.2132 
C 50- 21.1512 
74.1643 
0 281.4637 
40' 
1I1 5.17 
89.1 71 234.1378 
1071313 
2f8.1297 380.2512 
30 23.1 . 69 174 543 
' 250.11931 
148.1 9 213,1 13 
20 
jl 335.24 82 
149 40 198.172 . 
2799 
.1 18 2682 690 398.2666 
101 990 18"2 5' 30" 5 8" 32 5 . 
5008 362.285 
33 8 25 4h 337.9 414.4502 465.209 
50 140 230 320 410 501 
Mass (m/z) 
Figure 4.21. MALDI mass spectrum of a-cyano-4-hydroxycinnamic acid 
S 
3.5E+4 
II 
Mm ("112) 
Figure 4.20. MALDI mass spectrum of Cocaine 
146 
4.12. Conclusions 
1) MALDI-TOF-MS was evaluated as an analytical method that assumed the availability 
of a minimum amount of nail sample without prior extraction of the target analytes. The 
analytical data for opium alkaloids by MALDI-TOF-MS indicate that the technique was 
able to identify unextracted opium alkaloids. The opium alkaloids were easily measured, 
though the analytical conditions of the MALDI-TOF-MS were in the measurement mode 
used for polymers (peptide, etc. ) and there were interfering peaks derived from the matrix 
compound. 
2) If MALDI-TOF-MS was applied to analysis of illicit drug in the fingernail sample, 
there is a possibility to be able to analyse without extracting the drug in the ultra trace 
amount of the fingernail. 
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5. General Conclusions 
The aims of the work carried out for this thesis were outlined at the beginning of 
this report and were (a) to develop and assess improved methods of analysis for nail 
samples when used as an alternative matrix in forensic toxicology, (b) to evaluate this 
improved methodology for the analysis of nail specimens from controlled drug users and 
from doping steroid users and (c) to investigate instrumental methods of analysis which 
might be suitable for direct analysis of target analytes in very small samples of nail. All 
of these objectives were successfully achieved during the project. 
Nail has been shown to be an effective and useful sample in forensic toxicology and 
it is clear that nail analysis should be given more attention in future. A relatively 
convenient method of extracting illicit drugs from the difficult nail matrix based on 
cryogenic anabolic steroid users, respectively. It was found that this extraction method 
had the advantage grinding was developed and was applied to nail samples from cannabis, 
heroin and that analytes could be extracted directly without hydrolysis compared with 
previously used alkaline hydrolysis procedures. This method therefore overcomes the 
potential criticism of nail analysis based on alkaline hydrolysis, that the range of 
detectable analytes is unacceptably low, by extending the accessible range of analytes to 
include all of those which are now routinely analysed in hair. The results obtained 
indicate that analytes of a wide range of polarities are readily extracted from the finely 
ground nail powder. 
As a result, cannabinoids and opium alkaloids including heroin could be identified 
and determined in fingernails of cannabis and heroin abusers without chemical 
degradation of the target analytes, despite the fact that the analytes are present at low 
(ppb) concentrations. In particular, heroin could easily be detected without chemical 
degradation whereas it is difficult to identify heroin in conventional biological samples 
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such as blood or urine. Therefore, for these specimens, 6-monoacetylmorphine (6- 
MAM) is used as a biological marker for heroin use. The cryogenic grinding method was 
also successfully used for detection and identification of 6-acetylcodeine, papaverine and 
noscapine together with heroin in nail clippings. This study is the first to report detection 
of some of the impurities of street heroin in biological samples and suggests that they 
might be used in the near future as biological markers to prove that street heroin had been 
administered. 
Nail was shown to be useful as a forensic toxicology sample in a number of 
different contexts. In addition to abuse of street drugs, the cryogenic grinding method 
was applied to nail samples from doping steroid users. This approach might in future 
provide a viable alternative to hair and have a significant influence on fair play in sporting 
events. 
Endogenous anabolic steroids could be identified and determined in nail. The 
concentrations were found to be extremely low compared with those in urine and blood. 
However, exogenous anabolic steroids could only be tentatively identified and 
determined due to the presence of interfering endogenous compounds. Nevertheless, it 
seems probable that exogenous steroids are present in nail and can be extracted and 
analysed as for the drugs of abuse. The cryogenic grinding method is particularly 
valuable in this respect because many doping steroids are esters of testosterone and its 
analogues and would therefore be hydrolysed if the nail specimens were processed using 
an alkaline hydrolysis procedure. 
Finally, looking towards the future practical application of nail analysis, especially 
as an alternative to hair, an assessment was made of instrumental methods of analysis 
which might permit direct analysis of analytes in the nail matrix and which might pave 
the way for analysis of very small nail samples (microgram amounts). The value of this 
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would be to allow nails samples to be collected at different locations on the nail and not 
just from the tip, as it might take several weeks for drugs to reach the latter location. Hair 
analysis currently requires a period of 4 weeks for hair to grow until drugs in circulation 
and entrapped in the hair matrix emerge from the scalp. This forms the basis of the 
current protocol for date rape drug testing in hair. The techniques investigated (pyrolysis 
GC-MS and MALDI-TOF-MS) potentially might provide the basis of direct nail analysis, 
using microgram amounts of sample. However, the sensitivity of these instruments at 
present seems to be too low. 
Future Work 
The immediate need is to establish nail as a true and effective alternative for hair in 
forensic toxicology. This will require the collection and analysis of nail samples from a 
large number of drug abusers to establish concentration ranges and distribution patterns. 
Controlled dosing studies will be needed to establish the pharmacokinetics of the 
distribution of drugs and other substances into the nail matrix, their binding and 
elimination, if any, and the effects of cosmetic treatment on the analytes within the 
matrix. 
In addition, the use of deuterated internal standards of exogenous (synthetic) 
anabolic steroids is desirable for the analysis of exogenous steroids in nail clippings. 
Improved analytical methods based on GC-MS° or LC-MS° might overcome the 
interference that was found in this project, which used GC-MS only. It is anticipated that 
a method can be established which can allow the analysis of nail clippings without 
extracting the drug and in trace amounts of nail samples. When this is achieved, nail will 
become a very useful sample with a promising future. When MALDI-TOF-MS, a high 
sensitivity analytical method, was experimentally applied to opium alkaloids, excellent 
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analytical data were obtained. However, problems remain to be solved in this technique 
with respect to the introduction of nail samples and subsequent quantitation of the 
analytes. 
The final conclusion and observation which might be made are that the subject of 
drug analysis in nail is still in its infancy, at the stage of potential rapid development into 
which hair analysis entered more than ten years ago. The work described in this thesis 
has provided one route by which future progress might be made. 
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Appendix 
Table 3.8 is a database of doping steroids collected throughout research of this 
project. More than 600 kinds of the steroids collected consist of anabolic androgenic 
steroids, and its relative metabolites, estrogens, and progestagens. 
Notes: 
* Bold = steroids of stock (stored) 
** Bold and underline = purchased steroids 
*** Bold and double underline = synthesised steroids by author 
**** Bold, italic and underine = deuterated steroids. "-D" is put on the deuterated 
steroids behind the compound name. 
* Vol I- Vol 4= Recent advances in doping analysis, Sports & Buch Strauss, W. 
Schanzer et al. 
* Name of the number shows the same steroid name. 
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Table 3.8. (Continued) Database of doping steroids 
No . Cf., (Merck 12th ed, CAS No., Type etc. ) Literature 
N. Kumar, J. Steroid Biochem., 71 (1999) 213-222 
2 M0239; 24356-94-3; Cattle; Antiacne E. Daeseleire, J. Chromatogr., A 674 (1994) 247-253 
3 M0299; 432-60-0; Progestagen D. Courtheyn, Anal. Chim. Acta, 473 (2002) 71-82 
4 M0327; 850-52-2; Progestagen 
S M0674; 360-66-7 
6 Bolasterone-M4 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
7 RI=19.8 
8 1153-51-1 
9 18339-16-7 
10 65-06-5; RI = 25.7; Sb- = 10529-96-1 MH. Choi, Rapid Commun. MS., 13 (1999) 376-380 
11 10529-96-1; Boldenone-M2; RI = 2451 Schanzer W, Biol. Mass Spectrom., 21 (1992) 3-16 
12 Boldenone-M4 Schanzer W, Biol. Mass Spectrom., 21 (1992) 3-16 
13 571-40-4; Boldenone-M7; RI = 26.0 Schanzer W, Biol. Mass Spectrom., 21 (1992) 3-16 
14 21507-41-5; Boldenone-M6 Schanzer W, Biol. Mass Spectrom., 21 (1992) 3-16 
15 Boldenone-M3 Schanzer W, Biol. Mass Spectrom., 21 (1992) 3-16 
16 W. Schanzer, J. Steroid Biochem., 57 (1996) 363-376 
17 Cl-Methandrostenolone-M4, RI = 2997 W. Schanzer, J. Steroid Biochem., 57 (1996) 363-376 
18 Boldenone-M5 Schanzer W, Biol. Mass Spectrom., 21 (1992) 3-16 
19 M3268; 79-64-1; Progetagen 
20 Clostebol-M1; CLOS-MET; RI = 2691 L. D. Bowers, J. Chromatogr., B 687 (1996) 69-78 
21 382-44-5; RI = 28.4 W. Schanzer, Vol 4 (1996), p 199 
22 2,2,4,6,6,16,16-d7 W. Schanzer, Vol 4 (1996), p 191 
23 510-64-5 
24 M0174; 382-45-6; Nist#14350 
25 571-52-8; R1= 26.8 
26 M0678; 63-05-8; Androstenedione D. H. Catlin, Steroids, 67 (2002) 559-564 
27 Clostebol-M4 B. Bizec, Clin. Chem., 44 (1998) 973-984 
28 J . F. Dorgan, 
Steroids, 67 (2002) 151-158 
29 ( 98.4%) D. H. Kerkhof, J. Chromatogr., A 954 (2002) 199-206 
30 C lostebol-M7 B . Bizec, 
Clin. Chem., 44 (1998) 973-984 
31 F luoxymesterone-M2; RI = 2858 L . D. Bowers, 
J. Chromatogr., B 687 (1996) 69-78 
AM 
204 
32 1639-43-6; Androstenediol VP. Uralets, J. Anal. Toxicol., 23 (1999) 357-366 
33 566-48-3 
34 D. H. Catlin, Steroids, 67 (2002) 559-564 
35 63-00-3; RI = 27.6 (free-) J. F. Levesque, J. Chromatogr., B 780 (2002) 145-153 
36 25824-80-0 
37 2283-82-1; RI = 24.7 
38 M7892; 53-43-0; DHEA, Prasterone C. H. Shackleton, Steroids, 62 (1997) 665-673 
39 MO; 853-23-6; RI = 26.1 
40 23983-43-9 
41 16,16-d2 SJ. Gaskell, Label. Comp. & Radio., 17 (1980) 861-869 
42 MO; 571-36-8; Androstenedione 
43 
44 
45 
46 
47 85922-89-0; RI = 27.1 
48 1232-73-1; 16a-Hydroxy-DHEA 
49 M0677; 1963-03-7; RI = 25.0 (free-) L. D. Bowers, J. Chromatogr., B 687 (1996) 69-78 
50 RI = 27.6 C. H. L. Shackleton, Steroids, 62 (1997) 665-673 
51 M0677; 521-17-5; DHEA-M2 C. H. L. Shackleton, Steroids, 62 (1997) 665-673 
52 M0677; 5937-72-4 
53 M0677; 1175-12-8 
54 M0677; 1639-43-6 
55 M0677; 5953-63-9 
56 M0677; 116262-99-8 C. H. L. Shackleton, Steroids, 62 (1997) 665-673 
57 M0677; 2297-30-5; Bisexovis 
58 1159-66-6; RI = 26.3 
59 1449-61-2; RI = 28.4 I. Garret, Medical Hypotheses, 60 (2003) 391-397 
60 4-Cl-Methandrostenolone, 
Chloroxomesterone 
W. Schanzer, J. Steroid Biochem., 57 (1996) 363-376 
61 7738-93-4; Nist# 126775 
62 897-06-3; Boldenone-M8; RI = 26.5 Schanzer W, Biol. Mass Spectrom., 21 (1992) 3-16 
63 96301-34-7 
64 De-H-CI-Me-Testo. -M3 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
Al 
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65 De-H-Cl-Me-Testo. -M2 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
66 Boldenone-M9 Schanzer W, Biol. Mass Spectrom., 21 (1992) 3-16 
67 6ß-OH-deH-Cl-Testo. L. D. Bowers, J. Chromatogr., B 687 (1996) 69-78 
68 De-H-4-Cl-Me-Testo: M1 S. Rendic, J. Chromatogr., B 735 (1999) 73-83 
69 Boldenone-M10 Schanzer W, Biol. Mass Spectrom., 21 (1992) 3-16 
70 Fluoxymesterone-M5; RI = 2600 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
71 M0675; 438-22-2 K. R. Williams, University of Glasgow, Thesis (1999) 
72 M3912; 438-23-3; RI = 19.8 
73 963-74-6; RI = 22.6 C. Ayotte, J. Chromatogr., B 687 (1996) 3-25 
74 1912-614 V. P. Uralets, J. Anal. Toxicol., 24 (2000) 188-193 
75 1225-43-0; RI = 22.7 
76 2881-21-2; Dimethylandrostanolone 
77 7657-50-3; RI = 22.6 
78 M0680 
79 M0680 
80 M0680; 53-41-8; Testo. -M VP. Uralets, J. Anal. Toxicol., 23 (1999) 357-366 
81 MO; 53-42-9; Testo. -M VP. Uralets, J. Anal. Toxicol., 23 (1999) 357-366 
82 4-CI-Androsterone; Clostebol-M2 D. Thieme, Vol 4 (1996), pp 43-58 
83 4-C1-Etiocholanolone; Clostebol-M2 D. Thieme, Vol 4 (1996), pp 43-58 
84 16,16-d2 W. Schanzer, Vol 4 (1996), p 199 
85 16,16-d2 W. Schanzer, Vol 2 (1994), pp 93-112 
86 2,2,4,4-d4; RI = 2501 W. Schanzer, Vol 2 (1994), pp 93- 112 
87 2,2,4,4-d4; RI = 2519 W. Schanzer, Vol 2 (1994), pp 93- 112 
88 1224-95-9; RI = 22.9 
89 1236-13-1; RI = 23.9 C. H. L. Shackleton, Steroids, 62 (1997) 665-673 
90 1224-92-6; RI = 22.6 C. H. L. Shackleton, Steroids, 62 (1997) 665-673 
91 571-51-7; RI = 25.0 
92 M3646; 481-29-8; DHEA-MI B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
93 571-31-3; R1= 24.7 C. Ayotte, J. Chromatogr., B 687 (1996) 3-25 
94 Clostebol-M5 B. Bizec, Clin. Chem., 44 (1998) 973-984 
95 Clostebol-M; Cattle B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
96 Schanzer, Vol 3 (1995), pp 201-213 
97 1482-70-8 
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98 846-46-8; Testo. -M; RI = 25.8 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
99 1229-12-5; RI = 25.5; Testo. -M C. Ayotte, J. Chromatogr., B 687 (1996) 3-25 
100 B. Bizec, Clin. Chem., 44 (1998) 973-984 
101 Clostebol-M4 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
102 6165-21-5; RI = 24.2; 5a-DHT-M2 R. Aguilera, J. Chromatogr., B 727 (1999) 95-105 
103 5856-10-0; RI = 24.7; 17a, 5ßAD B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
104 RI = 26.9 C. H. L. Schackelton, Steroids, 62 (1997) 665-673 
105 RI = 26.1 C. H. L. Schackelton, Steroids, 62 (1997) 665-673 
106 Bolasterone-M2 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
107 Bolasterone-M B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
108 Calusterone-M3 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
10 91 1852-53-5; 5a-DHT-M1; AD; 5aAD L. D. Bowers, J. Chromatogr., B 687 (1996) 69-78 
11 0 1851-23-6; Testo. -M; 50AD C. H. L. Schackelton, Steroids, 62 (1997) 665-673 
11 1 1247-66-1; RI = 27.2 C. H. L. Schackelton, Steroids, 62 (1997) 665-673 
112 RI = 26.9 C. H. L. Schackelton, Steroids, 62 (1997) 665-673 
11 13 Calusterone-M2 W. Schanzer, Vol 4 (1996), p 193 
114 Calusterone-M1; Miboler. -M, Bolast: MI L. D. Bowers, J. Chromatogr., B 687 (1996) 69-78 
115 Calusterone-M2 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
116 Bolasterone-M 1; Calusterone-M1 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
117 Schanzer, Vol 3 (1995), pp 201-213 
118 Schanzer, Vol 3 (1995), pp 201-213 
119 1231-82-9; RI = 25.8 
120 739-27-5 
121 M0676; 514-17-0; RI = 27.2 (free) 
122 5856-11-1; RI = 25.7 R. Aguilera, J. Chromatogr., B 727 (1999) 95-105 
123 19767-69-2; RI = 24.4 
124 909-07-9; RI = 27.4 C. H. L. Shackleton, Steroids, 62 (1997) 665-673 
125 RI = 26.2 R. Aguilera, J. Chromatogr., B 727 (1999) 95-105 
126 B. Bizec, Clin. Chem., 44 (1998) 973-984 
127 571-20-0; Xenabol; WADA 2004 list C. Jimenez, Anal. Chim. Acta, 460 (2002) 289-307 
128 1852-53-5; Testo. -M; RI = 25.2 M. Ueki, Vol 3 (1995), p 245 
129 RI = 27.1 C. H. L. Shackleton, Steroids, 62 (1997) 665-673 
130 RI = 27.6 R. Aguilera, J. Chromatogr., B 727 (1999) 95-105 
207 
13 1 L. D. Bowers, J. Chromatogr., B 687 (1996) 69-78 
13 2 Schanzer, Vol 3 (1995), pp 201-213 
13 3 Schanzer, Vol 3 (1995), pp 201-213 
134 7090-90-6; RI = 25.9 
135 49643-99-4; RI = 26.8 
136 M1047; 4419-39-0; Antiallergic V. Cirimele, Forensic Sci. Int., 107 (2000) 381-388 
137 M1047; 5534-09-8; Aerobec R. Schilt, Analyst, 123 (1998) 2665-2670 
138 M1226; 378-44-9 Y. Gaillard, Foren. Sci. Int., 107 (2000) 361-379 
139 M1226; 2152-44-5 
140 M1352; 19793-20-5; Anabolic 
141 Norpropandrolate 
142 M1353; 1605-89-6; DiMe-Testo R. G-Lumbreras, J. Chromatogr., B 754 (2001) 419-425 
143 Metazine 
144 
145 ß-Boldenone-M 
146 M1354; 846-48-0 H. F. Brabander, J. Chromatogr., A 750 (1996) 105-114 
147 M1354; 2363-59-9 
148 19041-66-8 
149 M1354; 13103-34-9; Equipoise H. W. Hagedorn, Am. J. Vet. Res., 58(3), 224-227 
150 
151 1491-81-2 
152 M1771; 17021-26-0; Methosarb T. Kim, J. Chromatogr., B 687 (1996) 79-83 
153 M1795; 976-71-6; Diuretic R. G-Lumbreras, J. Chromatogr., B 754 (2001) 419-425 
154 M2152 P. Marchand, J. Chromatogr., A 867 (2000) 219-233 
155 M2152; 302-22-7; Progestagen E. Daeseleire, J. Chromatogr., B 562 (1991) 673-679 
156 M2423; 25122-46-7; Gluco; Anti-inflam. 
157 
158 M2475; 1093-58-9; RI = 2693 GP. Cartoni, J. Chromatogr., A 279 (1983) 515-522 
159 A. Koole, J. Chromatogr., B 724 (1999) 41-51 
160 M2475; 855-19-6; Steranabol A. Koole, J. Chromatogr., B 724 (1999) 41-51 
161 
162 
163 N. Kumar, J. Steroid Biochem., 71 (1999) 213-222 
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16 4 Quinbolone-M2 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
16 5 Quinbolone-MI B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
16 6, M8238; 1169-79-5; Estrogen 
16 7 
16 8 Anti-androgen 
169 M2875; 17230-88-5 D. DeBoer, J. Anal. Toxicol., 16 (1992) 14-18 
170 see M6018 
171 M2923; 72-23-1 
172 791-69-5 (9,11-dehydro) 
173 M2930; 13698-49-2 E. Daeseleire, J. Chromatogr., A 674 (1994) 247-253 
174 M2986; 50-02-2; Antiinflammatory E. Grippa, J. Chromatogr., B 2000 738 (2000) 17-25 
175 M8950; 521-18-6; Stanolone AT. Kicman, Clin. Chem., 41 (1995) 1617-1627 
176 see M8950; 571-22-2 
177 M8950 
178 
179 M8950 S. B. Coutts, Clin. Chem., 43 (1997) 2091-2098 
180 
181 
182 16,16-d2 Schanzer, Vol 3 (1995), pp 201-213 
183 16,16,17-d3 Schanzer, Vol 3 (1995), pp 201-213 
184 16,16,17-d3 Schanzer, Vol 3 (1995), pp 201-213 
185 M3504; 58-19-5; Antineoplastic E. Harber, J. Chromatogr., B 755 (2001) 17-26 
186 M3504 
187 M3504; 521-12-0; Masteron W. Schanzer, J. Chromatogr., B 687 (1996) 93-108 
188 M3510; 67392-87-4; Progestagen 
189 M3524; 152-62-5; Progestagen S. T-Cartas, J. Liq. Chromatogr., 24 (2001) 1089-1103 
190 GP. Cartoni, J. Chromatogr., A 279 (1983) 515-522 
191 M3646 
192 B. Bizec, Clin. Chem., 44 (1998) 973-984 
193 M3652; 547-81-9 
194 F luoxymesterone-M4 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
195 Methandrostenolone-M3; RI = 2625 R . Masse, J Chromatogr., 
B 562 (1991) 323-340 
196 Methandrostenolone-M W. Schänzer, J. Steroid Biochem., 38(19914) 441-464 
209 
19 71 1 
198 
199 Oxandrolone-M2; RI = 2666 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
200 MO; 481-30-1; RI = 2614 C. H. L Shackleton, Steroids, 62 (1997) 665-673 
201 RI = 2597 W. Schanzer, Vol 2 (1994), pp 93- 112 
202 M3662; 2363-58-8; Antineoplastic 
203 VP. Uralets, Vol 4 (1996), pp 35-41 
204 
205 M5659; 52-76-6; Contraceptive 
206 4409-34-1; RI = 28.0 R. Draisci, J. Chromatogr., A 870 (2000) 511-522 
207 M6814; 6795-60-4; Progestagen 
208 Norclostebol-M I B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
209 734-32-7; 19-Norandrostenedione VP. Uralets, J. Anal. Toxicol., 23 (1999) 357-366 
210 B. Bizec, Clin. Chem., 44 (1998) 973-984 
21 1 
212 19-Norandrostenediol VP. Uralets, J. Anal. Toxicol., 23 (1999) 357-366 
213 J. F. Levesque, J. Chromatogr., B 780 (2002) 145-153 
214 19-Nordehydroandrosterone 
215 19-Nordehydroepiandrosterone VP. Uralets, J. Anal. Toxicol., 24 (2000) 188-193 
216 3962-66-1; RI = 25.2 VP. Uralets, J. Anal. Toxicol., 24 (2000) 188-193 
217 
218 
219 
220 25975-59-1 (5,6-dehydro); RI = 24.2 
221 M6372; 34816-55-2; Estrogen 
222 39219-28-8; Estrogen 
223 1236-72-7 
224 362-08-3 L. Dehennin, J. Steroid Biochem., 20 (1984) 465-471 
225 362-07-2 L. Dehennin, J. Steroid Biochem., 20 (1984) 465-471 
226 Estetrol 
227 
228 
229 
210 
23 0 M6424; 5108-94-1; Estrogen 
23 1 M7969; 34184-77-5; Progestagen 
23 2 M3747; 57-91-0; RI = 25.8; ß-Estradiol-M S. Hartmann, J. Chromatogr., B 704 (1997) 105-117 
23 3 M3746; 50-28-2; Estrogen Y. Gaillard, J. Chromatogr., B 735 (1999) 189-205 
23 4 586-75-6; RI = 27.4 
23 5 313-06-4 
236 4956-37-0 
237 15140-27-9 
238 
239 3571-53-7 
240 979-32-8 
241 113-38-2 
242 M3746; 50-50-0; Pelanin R. Schilt, Analyst, 123 (1998) 2665-2670 
243 1035-77-4 
244 P. Marchand, J. Chromatogr., A 867 (2000) 219-233 
245 1434-85-1 
246 RI = 25.9 J. C. Mathurin, J. Chromatogr., B 759 (2001) 267-275 
247 RI = 25.3 J. C. Mathurin, J. Chromatogr., B 759 (2001) 267-275 
248 1225-01-0; Nandrolone-M1; RI = 2438 J. Munoz-Guerra, J. Chromatogr., B 704 (1997) 129-141 
249 33036-33-8; RI = 23.8; Nandrolone-M2 J. Munoz-Guerra, J. Chromatogr., B 704 (1997) 129-141 
250 Norclostebol-M3 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
251 Norclostebol-M2 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
252 3ß, 4ß, 5ß-d3 
253 3ß, 4ß, 5ß-d3 (Radiant-Promochem) L. Dehennin, J. Chromatogr., B 721 (1999) 301-307 
254 Nandrolone-M 
255 RI = 24.2 G. Debruyckere, Anal. Chim. Acta, 275 (1993) 49-56 
256 19-Norepiandrosterone-D3 
257 5 696-58-2; RI = 24.0 
258 R. Masse, J. Chromatogr., B 339 (1985) 11-23 
259 Norclostebol-M4 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
260 1 0002-97-8; RI = 24.0; Nandrolone-M 
261 E thylestrenol-MI, Norethndrolone-MI B . G. Wolthers, J. Chromatogr., 
B 843 (1999) 247-274 
262 E thylestrenol-M2, Norethandrolone-M2 J . Munoz-Guerra, J. 
Chromatogr., B 704 (1997) 129-141 
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263 see M3787; Progestagen J. C. Mathurin, J. Chromatogr., B 759 (2001) 267-275 
264 J. C. Mathurin, J. Chromatogr., B 759 (2001) 267-275 
265 Nandrolone-M; RI = 24.1 
266 Clostebol-M; Cattle 
267 M3750; 50-27-1; Estradiol-M S. Hartmann, J. Chromatogr., B 704 (1997) 105-117 
268 M3751; 53-16-7; Estradiol-M MH. Choi, Analyst, 125 (2000) 711-714 
269 M8239; 152-43-2; Estrogen 
270 M3780; 57-63-6; Estrogen H. F. Brabander, J. Chromatogr., A 750 (1996) 105-114 
271 M3787; 434-03-7 S. A. Hewitt, Anal. Chim. Acta, 473 (2002) 99-109 
272 M3851; 965-90-2; Maxibolein 
273 M3905; 1231-93-2; Contraceptive 
274 M3905; 297-76-7 
275 54048-10-1 
276 M4166; 127-31-1 S. Hartmann, J. Chromatogr., B 704 (1997) 105-117 
277 M4173; 2135-17-3; Glucocorticoid R. Draisci, J. Chromatogr., B 2001 (753) 217-223 
278 M4223; 76-43-7; Halotestin W. Schanzer, Steroids, 60 (1998) 353-366 
279 Fluoxymesterone-M1 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
280 M4235; 337-03-1; Progestagen D. Courtheyn, Anal. Chim. Acta, 473 (2002) 71-82 
281 M4266; 2454-11-7 GP. Cartoni, J. High Resol. Chromatogr., 14 (1991) 838-842 
282 M4319; 1239-29-8 T. Kim, J. Chromatogr., B 687 (1996) 79-83 
283 M4340; 6990-06-3; Antibacterial 
284 M4421; 60282-87-3; Progestagen 
285 M4422; 1253-28-7; Progestagen 
286 M4423; 16320-04-0 
287 M4628; 50629-82-8 
288 Formebolone-M 
289 
290 Formebolone-M2 S. Rendic, J. Chromatogr., B 735 (1999) 73-83 
291 Clostebol-M8 B. Bizec, Clin. Chem., 44 (1998) 973-984 
292 5 7-61-4 A. Heunerbein, J. Chromatogr., A 985 (2003) 375-386 
293 J . F. Levesque, 
J. Chromatogr., B 780 (2002) 145-153 
294 W. Schanzer, Vol 2 (1994), pp 93- 112 
295 W. Schanzer, Vol 4 (1996), p 191 
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296 S. Rendic, J. Chromatogr., B 735 (1999) 73-83 
297 J. F. Levesque, J. Chromatogr., B 780 (2002) 145-153 
298 W. Schanzer, J. Steroid Biochem., 57 (1996) 363-376 
299 Stanozolol-M M. Machnik, Vol 4 (1996), p 235 
300 570-30-9 
301 362-05-0; RI = 282 L. Dehennin, J. Steroid Biochem., 20 (1984) 465-471 
302 L. Dehennin, J. Steroid Biochem., 20 (1984) 465-471 
303 1229-24-9 L. Dehennin, J. Steroid Biochem., 20 (1984) 465-471 
304 L. Dehennin, J. Steroid Biochem., 20 (1984) 465-471 
305 
306 
307 RI=30.8 
308 
309 362-06-1; RI = 28.6; Estradiol-M L. Dehennin, J. Steroid Biochem., 20 (1984) 465-471 
3 10 3 13 1-23-5; RI = 30.2 L. Dehennin, J. Steroid Biochem., 20 (1984) 465-471 
311 
312 
313 1247-71-8; RI = 30.0 
314 Norethandrolone-M 
315 739-26-4; RI = 27.1; 11ß-OH-Androster: M A. Heunerbein, J. Chromatogr., A 985 (2003) 375-386 
316 
317 J. F. Levesque, J. Chromatogr., B 780 (2002) 145-153 
318 W. Schanzer, Vol 4 (1996), p 187 
319 W. Schanzer, Steroids, 60 (1998) 353-366 
320 Furazabol-M1 T. Kim, J. Chromatogr., B 687 (1996) 79-83 
321 Methandriol-M1 C. Ayotte, J. Chromatogr., B 687 (1996) 3-25 
322 Methandrostenolone-M A. R. McKinney, J. Chromatogr., B 765 (2001) 71-79 
323 273 handrostenolone-M2; Vol 4 pp. 242 & L. D. Bowers, J. Chromatogr., B 687 (1996) 69-78 
324 Formebolone-M1; RI = 3163 L. D. Bowers, J. Chromatogr., B 687 (1996) 69-78 
325 Oxymetholone-M (Proposed) V. Vladimirova, Vol 1 (1993) pp 101-120 
326 Oxymetholone-M (Proposed) V. Vladimirova, Vol 1 (1993) pp 101-120 
327 Oxymetholone-M (Proposed) V. Vladimirova, Vol 1 (1993) pp 101-120 
328 Oxymetholone-M (Proposed) W. Schanzer, Vol 1 (1993), p 99 
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329 Oxymetholone-M (Proposed) V. Vladimirova, Vol 1 (1993) pp 101-120 
330 D. DeBoer, Anal Toxicol., 16 (1992) 14-18 
331 Oxandrolone-Ml B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
332 
333 438-07-3 
334 M4886; 302-23-8 
335 M4886; 630-56-8; Hyproval; Progestagen 
336 M7251; 7001-56-1; Progestagen 
337 Stanozolol-M3; RI = 3334 V. Ferchaud, J. Chromatogr., B 695 (1997) 269-277 
338 Stanozolol-M1; RI = 3218; Vol 4, p. 232 W. Schanzer, J. Chromatogr., B 687 (1996) 93-108 
339 Stanozolol-M1; RI = 3238; Vol 1, p. 100 W. Schanzer, J. Chromatogr., B 687 (1996) 93-108 
340 Stanozolol-M2; RI = 3218; Vol 4, p. 233 W. Schanzer, J. Chromatogr., B 687 (1996) 93-108 
341 K. De Wasch, Anal. Chim. Acta, 473 (2002) 59-69 
342 
343 K. De Wasch, Anal. Chim. Acta, 473 (2002) 59-69 
344 MO; 1816-85-9; RI = 28.7 (free-) R. G-Lumbreras, J. Chromatogr., B 754 (2001) 419-425 
345 MO; 4075-20-1; RI = 28.2 (free-) 
346 MO; 2226-70-2 
347 MO 
348 MO; 63-01-4; RI = 283 (free) 
349 MO 
350 MO; 2126-37-6 
351 MO; 4075-14-3; RI = 27.2 (free) 
352 MO; 10390-14-4 
353 MO; 2944-87-8; RI = 27.8 (free) 
354 MO; 62-99-7 S. Rendic, J. Chromatogr., B 735 (1999) 73-83 
355 M5190; 338-95-4; Anti-inflammatory 
356 MO; 564-35-2; RI = 27.7 R. G-Lumbreras, J. Chromatogr., B 754 (2001) 419-425 
357 MO 
358 Dimethazine 
359 M5836; 977-79-7; Progestagen A. Koole, J. Chromatogr., B 724 (1999) 41-51 
360 M5838; 520-85-4 S . Hartmann, J. Chromatogr., 
B 704 (1997) 105-117 
361 M5838; 71-58-9 D. Hooijerink, Analyst, 119 (1994) 2617-2622 
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36 2 P. Marchand, J. Chromatogr., A 867 (2000) 219-233 
36 3 M5849; Progestagen P. Marchand, J. Chromatogr., A 867 (2000) 219-233 
36 4 M5849; 595-33-5; Progestagen E. Daeseleire, J. Chromatogr., B 562 (1991) 673-679 
36 5 P. Marchand, J. Chromatogr., A 867 (2000) 219-233 
36 6 M5859; 5633-18-1; Progestagen P. Marchand, J. Chromatogr., A 867 (2000) 219-233 
36 7 M5859; 2919-66-6; Progestagen I. G. Lange, J. Immu. & Imm., 24 (2003) 265-272 
36 8 P. Marchand, J. Chromatogr., A 867 (2000) 219-233 
369 M5904; 21362-69-6 
370 
371 M5973; 521-11-9; Androstalone 
372 M5974; 1424-00-6 R. Masse, J. Steroid Biochem., 42 (1992) 399-410 
373 M5974 
374 M5976; 72-33-3; Conovid 
375 M6017; 521-10-8 W. Schanzer, Anal. Chim. Acta, 275 (1993) 23-48 
376 M6017; 2061-86-1 
377 M6017; 3593-85-9; Probolin 
378 M6018; 72-63-9 R. Masse, J. Chromatogr., B 562 (1991) 323-340 
379 Methandrostenolone-M W. Schänzer, J. Steroid Biochem., 38(1991) 441-464 
380 Methandrostenolone-M W. SchAnzer, J. Steroid Biochem., 38(1991) 441-464 
381 Methandrostenolone-M W. Schänzer, J. Steroid Biochem., 38(1991) 441-464 
382 M6044; 153-00-4 W. Schanzer, Anal. Chim. Acta, 275 (1993) 23-48 
383 M6044; 434-05-9; Primobolan D. Goudreault, J. Steroid Biochem., 37(1990) 137-154 
384 M6044; 303-42-4; Primobolan Depot 
385 M2939; 10 11 6-22-0; Progestone 
386 Stenbolone-M5 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
387 Stenbolone-MI B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
388 S tenbolone-M D. Goudreault, J. Steroid Biochem., 38 (1991) 639-655 
389 S tenbolone-Ac-M D. Goudreault, J. Steroid Biochem., 38 (1991) 639-655 
390 Methenolone-Ac-M1-G D. Goudreault, J. Steroid Biochem., 37 (1990) 137-154 
391 S tenbolone-M3 D. Goudreault, J Steroid Biochem., 38 (1991) 639-655 
392 S tenbolone-M, Mesterblone-M 
393 M ethenolone-Ac-M1-G D. Goudreault, J. Steroid Biochem., 37(1990) 137-154 
394 M ethenolone-M B . G. Wolthers, 
J. Chromatogr., B 843 (1999) 247-274 
215 
395 Stenbolone-Ac-M4 D. Goudreault, J. Steroid Biochem., 38 (1991) 639-655 
396 Methenolone-Ac-M1-G D. Goudreault, J. Steroid Biochem., 38 (1991) 639-655 
397 
398 
399 
400 Oxandrolone-M2 B. G. Wolthers, J. Chromatogr., B 843 (1999) 247-274 
401 Mesterolone-M2; RI = 2604; Vol 3, p. 65 J. Munoz-Guerra, J. Chromatogr., B 704 (1997) 129-141 
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